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resumo 
 
 
O cancro do pâncreas é uma das doenças mais letais do mundo. A melhor 
esperança para reduzir a mortalidade provocada por este cancro reside no 
diagnóstico e tratamento precoces, mormente na deteção de lesões que 
podem conduzir ao seu desenvolvimento. Por outro lado, as terapias 
tradicionalmente aplicadas para combater o cancro do pâncreas têm vários 
inconvenientes, relacionados nomeadamente com uma eficácia limitada, 
toxicidade para os pacientes e aquisição de resistência aos medicamentos. 
Para contrariar esta tendência, tem sido dedicado um maior esforço na 
descoberta de novos fármacos anti-cancro pancreático, a partir de recursos 
naturais biológicos. Neste âmbito, organismos provenientes de ambientes 
marinhos (e.g., microorganismos simbiontes, algas, invertebrados) possuem 
um amplo potencial genético para a biossíntese de compostos naturais. No 
entanto, os ecossistemas marinhos estão ainda consideravelmente sub-
explorados para este propósito. Os simbiontes bacterianos marinhos, em 
particular, podem produzir vários metabolitos secundários com alto interesse 
biotecnológico, especialmente para aplicações biomédicas como as 
direcionadas para o tratamento anticancerígeno. Portanto, os principais 
objetivos deste trabalho foram: (1) desenvolver uma breve revisão sobre o 
cancro do pâncreas e suas atuais terapias, bem como sobre os produtos 
naturais bioativos e vias biossintéticas existentes em microorganismos 
marinhos; (2) desvendar o potencial de simbiontes bacterianos isolados de 
cnidários marinhos para sintetizar compostos bioativos contra o cancro do 
pâncreas. Algumas bactérias têm o potencial de sintetizar novos produtos 
através da atividade das enzimas policetídeo sintases (PKS), sintetases 
peptídicas não ribossomais (NRPS), ou uma combinação de ambas. Estas 
enzimas multifuncionais produtoras de policetídeos (PKs), péptidos não 
ribossomais (NRPs) ou híbridos PKs-NRPs podem ter várias estruturas 
químicas e bioatividades (e.g., antimicrobiana, antioxidante, anti-inflamatória, 
anticancerígena). O rastreio molecular de fragmentos do gene NRPS em 
simbiontes bacterianos marinhos de cnidários evidenciou a sua presença em 
22,3% dos isolados, os quais pertencem aos filos Proteobacteria e 
Actinobacteria. A maioria das sequências de aminoácidos obtidas para o grupo 
de bactérias selecionadas por serem potenciais produtores de NRPs, 
apresentou uma homologia relativamente elevada em relação a sequências de 
aminoácidos depositadas para NRPS. Além disso, os extratos preparados a 
partir das frações celulares e sobrenadante de culturas das bactérias 
selecionadas inibiram significativamente a atividade de uma linha celular 
humana de adenocarcinoma do ducto pancreático, mediante o ensaio MTT. 
Assim, o potencial anticancerígeno dos simbiontes bacterianos de cnidários 
demonstrou ser promissor, pelo que o seu estudo deve ser mais aprofundado 
no futuro. 
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abstract 
 
 
 
Pancreatic cancer is one of the deadliest diseases in the world. The best hope 
for reducing mortality by cancer lies in its early diagnosis and treatment, 
namely in the detection of lesions that can evolve into cancer stages. On the 
other hand, traditionally applied therapeutics to fight pancreatic cancer have 
several drawbacks, namely related with limited efficacy, toxicity to patients, 
and acquisition of drug resistance. As to counteract this trend, a greater effort 
has been devoted to the discovery of new anti-pancreatic cancer drugs from 
biological natural resources. In this context, organisms from marine 
environments (e.g., microbial symbionts, algae, invertebrates) possess a wide 
genetic potential for the biosynthesis of natural compounds. However, marine 
ecosystems are yet severely overlooked for that purpose. Marine bacterial 
symbionts, in particular, can produce several secondary metabolites with high 
biotechnological interest, especially for biomedical applications like those 
directed to anticancer treatment. Therefore, the major goals of this work were 
to: (1) develop a brief review on pancreatic cancer and current therapeutics, as 
well as on the pool of natural products and associated biosynthetic pathways in
marine microbes; (2) unravel the potential of bacterial symbionts isolated from 
marine cnidarians to synthesize bioactive compounds against pancreatic 
cancer. Some bacteria have the potential to synthesize new products through 
the activity of the modular enzymes polyketide synthases (PKS), nonribosomal 
peptide synthetases (NRPS), or a combination of both. These multifunctional 
enzymes are involved in the production of polyketides (PKs), nonribosomal 
peptides (NRPs) or PKs-NRPs hybrid compounds that can have various 
chemical structures and bioactivities (e.g., antimicrobial, antioxidant, anti-
inflammatory, anticancer). The molecular screening of NRPS gene fragments 
in marine bacterial symbionts of cnidarians showed their presence in 22.3% of 
the isolates, which belong to Proteobacteria and Actinobacteria phyla. Most 
aminoacid sequences obtained for a selected group of these potential NRPs-
bacterial producers presented a relatively high homology with deposited 
aminoacid sequences of NRPS clusters. Furthermore, crude extracts prepared 
from the cell and cell-free fractions of cultures from the selected bacteria could 
generally significantly inhibit the activity of a human pancreatic ductal 
adenocarcinoma cell line, according to the MTT assay. Thereby, the anticancer 
potential of cnidarian bacterial symbionts was promising, hence reinforcing the 
need for deepening its study in the future.  
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1-Pancreatic cancer: what is it and how it evolves? 
 
Pancreatic cancer is estimated to be the 7th deadliest cancer in the world in 20181, due to 
its fast progress, high malignancy and early metastasis, making therapeutics efficacy practically 
impossible for most patients2,3. Early detection gives hope for a cure, but its lack of symptoms 
transforms pancreatic cancer diagnosis quite difficult and unsuccessful3.  
 
1.1-Epidemiology & etiology 
 
1.1.1- Incidence and mortality rates 
 
Pancreatic ductal adenocarcinoma (PDAC) and its variants is responsible for 85-90% of all 
pancreatic neoplasms, being thereby most commonly called as pancreatic cancer4. Globally, there 
is a prediction for the year of 2018 of about 458,918 new cases of pancreatic cancer, representing 
2.5% of all cancers, and 432,242 deaths (4.5% of all cancers deaths)1. According to GLOBOCAN 
statistics for the year 2012, 338,000 new cases (2.4% of all cancers) and 331,000 deaths (4% of all 
cancers deaths) were recorded5, what clearly suggests an increased impact of this disease. 
Pancreatic cancer incidence rate for men and women is around 5.5 individuals per 100,000 and 
4.0 individuals per each 100,000, respectively1. For both sexes, however, it has been observed an 
increasing incidence of pancreatic cancer with age, and most diagnosed cases occur after the 55 
years of age6,7. In what concerns its worldwide incidence, this disease has been mostly diagnosed 
in developed countries, where 55.5% of new cases occurred in the year of 20125. For 2018, is 
estimated higher incidence rates for both genders in Eastern Europe (9.9 per 100,000 men, and 
5.8 per 100,000 women) and Western Europe (9.5 per 100,000 men, and 7.2 per 100,000 
women), comparatively to those previewed for Northern America (8.7 per 100,000 men, and 6.5 
per 100,000 women) and Australia/New Zealand (7.4 per 100,000 men, and 6.4 per 100,000 
women)1. 
 
 1.1.3- Risk factors 
 
Among the risk factors for PDAC development, they can be roughly divided into intrinsic 
and extrinsic factors. As intrinsic factors, genetic mutations at different genes like KRAS (encode 
for proteins that normally promote the abnormal proliferation of cancer cells8,9), Tp53 (tumour 
suppressor gene that when is mutated enhances tumour growth9 through the control of DNA 
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damage responses), BRCA1/BRCA2 (associated with the regulation of DNA repair10), PALB2 
(chromatin adaptor for BRCA2 and promotes the connection between BRCA1 and BRCA211) and 
CDKN2A12 (tumour suppressor gene that when altered causes chromosomic mutations leading to 
tumor growth13), can trigger PDAC carcinogenesis9. Similarly, several pancreatic diseases may 
promote PDAC pathogenesis. The most concerning one is diabetes, as far as it arises from the 
dysregulation of pancreatic function. On the other hand, diabetes can be a manifestation of PDAC, 
especially in the case of type I (chronic) diabetic patients. However, type II diabetes can indeed be 
a major pancreatic cancer triggering factor, because it increases the risk of hyperglycaemia due to 
the impairment of glucose levels in blood14,15, which increase cancer risk by guaranteeing the 
prevalence and evolution of KRAS mutations15,16. Chronic pancreatitis also provides an increased 
risk of advancing into PDAC as a result of a large number of cell divisions due to the disruption of 
DNA repair systems17. Obesity may as well promote the appearance of PDAC since adipose tissues 
may boost inflammatory and hormonal responses, besides the potential disruption of the energy 
balance related with an increase of food consumption18 and induction of chronic 
hyperinsulinemia19,20. Inherited genetic susceptibility is also a PDAC risk factor, existing the 
possibility of familial pancreatic cancer associated with susceptibility loci20. Age, gender, blood 
group and ethnicity (related to the incidence among countries/continents) constitute as well 
intrinsic factors affecting PDAC development and incidence4.  
Additional external or behavioural factors associated with PDAC are dietary habits, 
alcohol consumption and smoking7,21,22, being the last one a great contribution to the occurrence 
of DNA damages/mutations in pancreatic cells that further promote initiation and proliferation of 
PDAC23,24.  
 
1.1.4- Types of pancreatic cancer by their location 
 
Malignant pancreatic tumours can be classified according to their location, i.e., in the 
exocrine (ductal or acinar cancers) or endocrine pancreas25. As aforementioned, the exocrine 
ductal epithelial adenocarcinoma is responsible for about 90% of the cases4, while the endocrine 
cancer is more rare25. The two types are heterogeneous and have different histological and 
clinical features, as well as different epidemiologic expression26. It is also possible to find a 
combined tumour with exocrine and endocrine location, although this is not very frequent. This 
pancreatic cancer type is usually characterized by an exocrine-ductal component, in which the 
endocrine tumour may represent ca. one third to one half of the total tumour25.  
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1.2- Diagnosis  
 
Current diagnostic techniques of PDAC rely on imaging and/or blood analyses. Among the 
available imaging tests there are computerized tomography scanning, magnetic resonance 
imaging, endoscopic ultrasonography and endoscopic retrograde cholangiopancreatography. 
However, these are expensive, may be invasive, require more time for achieving the results and 
cannot accurately detect tiny lesions at a premalignant stage27. In turn, the most common blood 
(serum) biomarkers known for pancreatic cancer diagnosis and monitoring of response to 
therapeutics are proteins/epitopes like CA 19.9, CA50, CA125, Laminin gamma C and CEA28,29. 
Nevertheless, these markers may present drawbacks related with low sensitivity and uncertainty 
to accurately detect PDAC. For instance, CA 19.9 is not expressed in Lewis-negative phenotype 
(Lewis antigen system based on chromosome 19/Lewis gene) and may even give false positives in 
the presence of obstructive jaundice30.  
So, the currently available diagnostic tools and markers fail to provide the occurrence of 
PDAC within a safe period for its effective treatment, what combined with its strong metastatic 
behaviour and resistance to current therapies, makes it a life-threatening disease. Therefore, 
there is an urgent need for an ideal biomarker that facilitates pancreatic cancer detection. In this 
context, there are three main steps that need to be performed for an early detection and 
treatment of pancreatic cancer. The first is to distinguish the lesions that leads to advanced 
pancreatic cancers. Second, there should be an opportunity to detect those curable lesions 
through the creation of a sensitive screening test capable of responding along the disease 
progression time. Third, the disease prevalence in the population must be high enough to be 
accurately screened by the tests3. 
 The search for new biomarkers towards the early diagnosis of PDAC may rely on crucial 
pathways or mechanisms responsible for its proliferation, namely the formation of pre-metastic 
niches, which precedes distant metastasis from primary tumour site. Exosomes are microvesicles 
derived from pancreatic lesions that have a role in the formation of pre-metastatic niches in 
liver31 and other body locations like breast and lungs32. The Kupffer cells (KCs) in the liver 
phagocytize exosomes from the blood stream, hence activating fibrotic pathways and pro-
inflammatory responses (e.g., synthesis of fibronectin and transforming growth factor β) leading 
to a metastatic microenvironment31. The circulating exosomes can therefore be explored as 
biomarkers for pancreatic cancer, though the cellular and molecular mechanisms by which 
exosomes alter metastasis are yet to be established. Some experiments in mice carrying PDAC had 
focused on how the upregulation of migration inhibitory factor is a main event during cancer 
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progression, which can be detected in exosomes isolated from the plasma of mice and patients 
with PDAC31.  
 
1.3 -Biology and carcinogenesis  
 
1.3.1- Carcinogenesis  
 
 
Pancreatic cancer possess a multifaceted biology and its current knowledge assumes that 
it is constituted by several components, such as pancreatic cancer somatic cells and stem cells, 
and the tumour stroma33. In particular, the pancreatic cancer stellate cells (i.e., myofibroblasts), 
are the main components of the tumour stroma33. In what concerns cancer stem cells in the 
primary tumour, they have been pointed out as the responsible for shorter patients’ survival, 
resistance to chemo- and radiotherapies, as well as for the increasing of PDAC metastatic 
potential34,35.  
Pancreatic cancer may begin with a with gene mutation(s) and/or pancreatic lesions. In 
what regards genetic mutations in normal pancreatic cells, they may target genes involved in 
several signalling pathways like RAS-ERK signalling (extracellular signal-regulated kinase 
signalling pathway) , G1/S phase transition (checkpoint in cell cycle), DNA damage response, TGFβ 
(transforming growth factor beta ) signalling, SWI/SNF (SWItch/Sucrose Non-Fermentable) 
pathway, KMT2 (family of methyltransferases), cell stress response, axonal guidance, RNA 
splicing, homophilic cell adhesion36,37. Regarding the inherited genetic susceptibility, the disabling 
of DNA repair system-encoding genes (e.g., BRCA1, BRCA2, Fanconi anaemia FANCC and FANCG, 
ataxia telangiectasia mutated genes) have been associated with an increased risk of PDAC38,39. 
Also mutation on genes involved in cell division cycle [e.g., the genes cyclin-dependent kinase 
inhibitor 2A (CDKN2A)15,38,40, nuclear receptor subfamily 5 group A member 2 (NR5A2), telomerase 
reverse transcriptase (TERT), zinc ring finger 3 (ZNFR3) and TP63]41–43 have been studied. Overall, 
a single mutation alone is not enough for tumour development15 due to the poor proliferation 
capacity of the pancreatic tissue44. As such, cells divide and increase their number, ending up in 
cellular populations with the same driver gene mutation, leading to clonal expansion. Hence, the 
tumour propagates upon increasing cell divisions, consequently enabling the accumulation of 
somatic alterations15,45 that are responsible for pancreatic cancer heterogeneity. The (population 
of) cells carrying mutations can afterwards cross the surrounding membrane and disperse to 
other near or distant locations/organs, hence forming metastases. For that, pre-metastatic niches 
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are developed through several events that help establishing the tumour microenvironment in 
distant metastatic sites, thereby leading the flux of cancer cells from the primary tumour to those 
sites, while simultaneously guaranteeing the survival of the newly arrived metastatic cells46,47. As 
briefly referred in the previous section, metastatic cells may rely on tumour-derived 
exosomes48,49, which are microvesicles (ca. 30-150 nm diameter) of endocytic origin constituted 
by extracellular matrix components50–54, with a key role on intercellular communication between 
cancer cells and their respective microenvironment. Exosomes abundance has been normally 
correlated with tumour malignancy55, since they contribute for the successful adhesion and 
colonization of circulating cells into other tissues56, hence mediating the process of metastases 
dissemination and  tumour development/proliferation15.  
There are evidences that premalignant lesions in normal ductal epithelium, such as 
Pancreatic Intraepithelial Neoplasia (PanIN), have also a strong involvement in cancer 
development57, though 16 to 45% of them are not associated with invasive carcinomas58,59. These 
lesions occur and start in the small ducts of the exocrine pancreas33. According to their neoplastic 
progression and stage, they may be classified as PanIN-1 (low grade), PanIN-2 (medium grade) or 
PanIN-3 (high grade)60,61. The PanIN-1 lesions are observed in normal pancreatic tissues, whilst 
PanIN-2 occur in the tissue of neoplastic pancreata, and PanIN3 lesions are usually associated 
with an established pancreatic cancer. The mutations responsible for PanIN progression into a 
carcinoma frequently rely on the activation of KRAS2 oncogene (most frequent and it occurs in 
95% of pancreatic tumors), and inactivation of tumour suppressor genes such as CDKN2A, INK4A, 
TP53 and DPC4/SMAD415,34,62,63. Although PanIN are major cancer-inducing lesions, other 
pancreatic neoplasic lesions may be indeed precursors of invasive carcinomas, namely the 
intraductal papillary mucinous neoplasm (IPMN) and mucinous cystic neoplasms (MCN)3.  
The biochemical and metabolic traits associated with PDAC development highlight the 
capacity of changes in cell functions that are needed for tumour initiation and progression64.  A 
such, besides the high energetic (i.e., ATP) and biochemical (several macromolecules) 
requirements to support PDAC proliferation, tumour microenvironment partly sustained by 
desmoplastic stromal reactions is also an extremely relevant influencing factor. The stroma is the 
connective and structural part of a tissue, but in PDAC the characteristic desmoplastic stroma is 
enhanced comparatively to the epithelial counterpart of the tumour, being responsible for the 
hypoxic and low nutrient loads determined in PDAC metabolic features65–67. Moreover, PDAC is 
indeed typically characterized by a fibroinflammatory microenvironment, which induce T cells 
that possess a mechanism of p38 protein kinase activation (MAPK)68, which lead to an enhanced 
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production of cytokines69,70. The  microenvironment of PDAC is the major source of tumour-
promoting cytokines that cause angiogenesis, metastasis, and resistance to chemotherapy and 
disruption of the host defences71–73. Angiogenesis, in particular, promotes the formation of a 
dense blood vessels net what is very important towards the growth, invasion and metastasization 
of the tumours, as far as it provides nutrients and oxygen to the tumour cells74,75. Furthermore, 
angiogenesis entails the proliferation and migration of endothelial cells. Some growth factors are 
part of tumour angiogenesis such as the fibroblast growth factor, epidermal growth factor, 
vascular endothelial growth factor, placental growth factor, tumour necrosis factor-alfa (TNF-α), 
and angiogenin 76–78.  
1.3.2- Apoptosis pathway 
 
 Together with the cancer pathways mentioned above, other pathways like Hedgehog 
pathway, integrin signalling, JNK, Wnt-β-caterin, Small GTPases and mainly apoptosis67, have very 
important roles in PDAC development. Herein is described the apoptosis pathway in particular 
since it is one of the first mechanisms that act against cell dysregulation in our system, and hence 
give some information on how the disease can be treated. Besides, apoptosis functions in 
combination with the other signalling pathways, therefore maximizing its potential to eliminate 
cancer cells79. Plus, it is a natural mechanism to prevent cancer dissemination by killing the 
dysregulated cells, but it can also influence cell mutations when cancer cells can escape from 
programmed cell death80. So, apoptosis is not always a safe pathway, and can actually favour 
disease proliferation under certain circumstances79.  
Apoptosis is a natural programmed cell death that emerges from two specific pathways in 
cells. The first is extrinsic to the cell and depends on its surface receptors. The second is an 
intrinsic pathway lead by mitochondria-produced molecules81. A strong therapeutic strategy is to 
block the apoptosis pathways in cancer cells78,82. Some peptides are responsible to induce 
apoptosis in such cells, which makes them potential targets of treatment. Necrosis is another 
relevant natural cell death pathway, though not programmed. Necrosis involves the degeneration 
of cell cytoplasm, causing the release of cytoplasmic contents78,83,84. Apoptosis and necrosis can 
be originated by physical traumas to the cells or pathological cell damages85,86.  
In the human body are generated radicals called reactive oxygen species (ROS), such as 
the superoxide anion (O-2), hydrogen peroxide (H2O2), hydroxyl radical (OH) which are derived 
from oxygen metabolism and help to balance the oxidative homeostasis in normal cells87,88. 
Therefore, depending on its levels, ROS can either be beneficial for cell functioning or harmful81,89. 
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Free radicals and ROS produced in normal cell metabolism are beneficial (at reasonable 
concentrations) because of the regulation of intracellular redox signalling90–92. Some ROS can even 
induce the production of anticancer molecules like phenethylisothiocyanate, which promote 
pathways committed to the selective killing of cancer cells81. However, if the antioxidant systems 
are inhibited and/or an excess of ROS is produced in response to oxidative stress scenarios, then a 
loss of cellular functions and even apoptosis may take place93. Pancreatic cancer cells create 
medium levels of ROS to operate in their proliferation, migration and metastasis. Nevertheless, if 
ROS levels are too high it can promote PDAC cell death, because they create an adverse 
environment81,94–96. 
Some natural compounds influence apoptosis by interacting with different signalling 
pathways targets, like transcription factors, protein kinases, angiogenesis, and inflammatory 
cytokines that are often unbalanced in cancer stages81. Available studies confirm that using 
Nimbolide (a plant secondary metabolite) to induce overexpressed levels of ROS could inhibit 
pancreatic cancer proliferation and migratory capacity through the regulation of apoptosis and 
autophagy15. Besides natural compounds, we possess our own proteins that function like tumour 
suppressor p53 that is a known example of protein responsible for protecting genome stability 
and have a very important role in the control of cell cycle, apoptosis, maintenance of genomic 
integrity and DNA repair in response to cell stress97,98. When p53 is activated it attaches to 
regulatory molecules that enhances the expression of specific genes leading cells response against 
tumour formation9. 
 
1.4- Pancreatic cancer therapeutics 
 
Surgery remains the most used method for controlling pancreatic cancer in an attempt of 
therapeutic cure, because there is still no effective treatment and the available disease 
screening/diagnostic methods are not robust enough to detect pancreatic cancer at a more 
curative stage78,99. Notwithstanding, in some cases PDAC surgery may be supported by adjuvant 
therapies that usually include chemotherapeutic treatments relying on the administration of e.g., 
gemcitabine or 5-fluorouracil (5-FU). However, some studies were explored the effect of 
combining these drugs with other chemotherapeutics like capecitabine, pemetrexed, erlotinib, 
irinotecan, exatecan, and/or targeted therapies78,100–102, though they revealed not to be effective 
yet. 
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One of the major problems tailoring therapeutic effectiveness is the different cancer 
phenotypes, which may develop resistance to anticancer compounds or even to pro-apoptotic 
effects. Therefore, it is important to have this into consideration, and gather a robust knowledge 
on PDAC phenotypes of each tumour for applying adjusted and more precise therapeutics103.  
In this context, targeted therapies (e.g., hormone therapy, immunotherapy) have been 
the target of many studies for that purpose as already referred, though it is yet on its infancy. A 
variety of bioactive peptides capable of modulating immune responses can be explored as new 
anticancer drugs and used towards cancer immunotherapy103. Those peptides can provide many 
advantages relatively to conventional chemotherapeutics, such as high selectivity, favourable 
pharmacokinetic action, easy to access tumor sites, generally low toxicity and immunogenicity. 
although they have a weakness due to their limited stability and difficulties in penetrating cell 
membranes103.  
Bacterially-based therapies have also been raising interest among the biomedical 
scientific community. Some bacteria like Salmonella typhimurium A1-R have been explored to 
help suppress tumour growth. The action of bacteria does not involve exerting a direct cytotoxic 
effect on tumour cells, but instead inducing the expression of anticancer agents through 
chemotaxis104. Notwithstanding, Salmonella may induce negative side-effects due to infection 
development105. Thereby, major challenges should be addressed regarding toxicity, ability to 
specifically reach the tumour site and attain regions not easily reachable by current treatments105, 
bacteria proliferation in tumour microenvironment and capacity to be genetically engineered105. 
Anyway, bacteria are offering and opening new therapeutic possibilities, which have been also 
associated with their enormous potential of biosynthesis of bioactive secondary metabolites or 
natural products. The combination of these bacterially-based therapies with chemotherapeutic 
agents can indeed contributes to a new era of alternative PDAC treatments in the future. 
 
2- Search for new anti-PDAC natural products 
 
Nowadays, novel compounds have been urgently claimed by clinics in order to overcome 
the limitations of current PDAC therapeutics, which range from toxicological side-effects, low 
specificity and efficacy, to multidrug resistance105. As such, focusing the discovery of new drugs on 
natural resources has been encouraged again, particularly by the pharmaceutical industry, given 
the need to find novel chemical structures with enhanced anticancer activity, more easily 
absorbed, stable, less toxic and highly tumour-specific. In a chemical perspective, natural products 
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are broadly considered as molecules with varied structures and molecular weights that belong to 
different chemical classes (e.g., peptides, fatty acids, nucleosides) and may present, besides 
anticancer activity, antifungal, antiviral, antibiotic, anti-inflammatory and/or antioxidant 
activities106. Given their variety and range of potential applications, the number of studies 
devoted to the search of bioactive natural products synthesized by living organisms from different 
environmental sources has been increasingly rising in the last decades80. The aquatic107 or 
terrestrial environments108 are two major compartments targeted for searching natural 
compounds. In particular, ecosystems characterized by extreme conditions of temperature, pH, 
pressure, oxygen availability, nutrient loads and contamination profiles109, or even under-explored 
environments (e.g., the marine environment108) may offer great pharmaceutical opportunities. 
This is because the organisms inhabiting such extreme environments developed genetic, 
metabolic and physiological adaptations to withstand harsh conditions. Thereby, different 
organisms have been explored for their potential to synthesize bioactive molecules through a 
secondary metabolism that often results from that evolutionary selection or adaptation110. 
Although the ecological role of the secondary metabolites may not be thoroughly disclosed or 
known for many organisms, it has been referred their role on organisms’ responses as to endure 
and proliferate under stressful conditions (e.g., acidic pH, chemical contamination)111 and species 
interrelations (e.g., interspecies competition, quorum sensing111, microbial pathogens)112,113.  
Among the organisms producing bioactive compounds with anti-PDAC activity, plants 
have been demonstrating a great potential. Curcumin, which was isolated from a turmeric plant, 
has antitumor, antioxidant and anti-inflammatory properties112. The anticancer properties of 
curcumin are derived from its capacity to block the transcriptional nuclear factor kappa beta 
(NFkb), which is a cancer cell regulator in inflammatory, proliferation, apoptosis and multidrug 
resistance114. In fact, a curcumin analogue, GO-Y030, has been found to be even more active 
against STAT3115, a signal transducer and activator of transcription 3 that is associated with 
promotion of metastasis in PDAC115. Capsaicin, which is the main compound of chilli pepper 
plants, has been used to fight multidrug resistance. Capsaicin targets Trx-ASK1 (apoptosis signal-
regulating kinase) to induce apoptosis in BxPC-3 cells, a line of pancreatic adenocarcinoma cells106. 
Mogroside V was another compound isolated from a Chinese plant that inhibits the survival of 
PANC-1 cells, leading to apoptosis by blocking cell division at the G0/G1 phase116. It also 
upregulates genes like CDKN1A (that is controlled by p53) and CDKN1B functioning as cyclin 
kinase inhibitors and tumour suppressors. It is suggested that Mogroside V can indeed control 
PDAC growth by angiogenesis inhibition through the VEGF (vascular endothelial growth factor)-
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dependent mechanism116. In fact, since Mogroside V can be daily consumed as a food sweetener, 
it may be used as a preventive natural treatment against PDAC116.  
Great part of the work developed recently has also been directed to get further 
knowledge on the secondary metabolites produced by bacteria, mainly from Actinobacteria 
phylum117. The biosynthesis of natural products by bacteria is sustained by different enzymes, 
being the most known, the polyketide synthases (PKS)118 and nonribosomal peptide synthetases 
(NRPS)119. These multifunctional and modular enzymes mediate the production of polyketides 
(PKs) and nonribossomal peptides (NRPs) compounds120. For more details on these biosynthetic 
pathways and genetic machinery, please see Chapter II. 
 
2.1- Marine sources of natural compounds 
 
 
The marine ecosystem corresponds to 95% of the Earth biosphere and has been pointed 
out as a great provider of multiple sources of bioactive natural compounds121,122 Among the 
marine organisms, bacteria, cyanobacteria, archaea, fungi, micro- and macroalgae, and even 
invertebrates have been explored for the extraction and purification of natural compounds that 
exhibit several properties with significant biological activities, such as anticancer, anti-
inflammatory, antiviral, antibacterial and anticoagulant112,123. Overall, despite some of the marine 
natural products discovered so far present anti-PDAC activity, the potential of marine ecosystems 
to provide additional drug options is far from being deeply known or covered. 
 
2.1.1- Bacteria and Archaea 
 
Among the marine microbes, representatives of Archaea and Eubacteria kingdoms have 
been investigated for new and diverse metabolites with bioactivity112. Although these microbial 
groups are geographically ubiquitous, Archaea are often identified in extreme environmental 
conditions like in deep sea and thermal vents112. But bacteria can also withstand a wide range of 
environments and hostile conditions110. Given their adaptations, marine bacteria evolved abilities 
associated with the production of many secondary metabolites. Different peptides synthesized by 
bacteria revealed to be promising compounds for medical applications, for example, lasso 
peptides124, bacteriocins like microcins, colicins and lantibiotics124, and nonribosomal peptides like 
cyanobacterial peptides112. Cyanobacteria were found to produce anabaena peptides (from 
Anabaena sp.), cyanopeptolins (a class of oligopeptides produced by Microcystis), aeruginosins 
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(protease inhibitors produced by Microcystis aeruginosa) and microviridins (serine protease 
inhibitors produced by various genera of cyanobacteria)112.  Other type of bacteria, Myxobacteria, 
have a complex life cycle and are proved to be a useful source of natural compounds with huge 
potential for new drugs125. In marine Actinobacteria, the genus Streptomyces produces almost 
80% of the natural compounds of Actinomycete126. Streptomyces species are producers of 
compounds with some properties like antifungal (e.g., natamycin), antibacterial (e.g., 
streptomycin), and antiparasitic (e.g., ivermectin) activities194-196. Against PDAC, was particularly 
found capsimycins derived from Streptomyces xiamenensis that induced cytotoxicity against 
several pancreatic cancer cell lines129.  
 
2.1.2- Fungi 
 
Marine fungi as Acremonium, Aspergillus, Fusarium, Epicoccum and others genera130 often 
live as symbionts of marine algae or invertebrates112,123, evidencing the ability to synthesize 
several compound like PKs, alkaloids112,131, sesquiterpenes112, and aromatic compounds23,132. 
These natural products were discovered to induce cytotoxic, neuroactive, antibacterial, antiviral 
and antifungal activities131,133. Penicillium chrysogenum is a penicillin producer, whilst Penincillium 
griseofulvum is a producer of griseofulvin (for antifungal treatment) and are the most studied 
biosynthetic fungi130. Another marine fungi representative of the genus Trichoderma are also 
producers of several different bioactive metabolites, like the antimycobacterial aminolipoptide 
trichoderins134 and the antifungal trichodermaketone A135. Varioxepine is a recently discovered 
alkaloid isolated from the endophytic fungus Paecilomyces variotii (lives in association with an 
algae) that has activity against the phyto-pathogenic fungus Fusarium graminearum136. 
 
2.1.3- Algae  
 
 
 Algae are photosynthetic organisms, and major producers of biomass and organic 
products in the marine environment112. Marine microalgae include five groups, Chlorophyta, 
Chrysophyta, Pyrrhophyta, Euglenophyta and Cyanophyta112. Microalgae are considered a great 
source of natural bioactive compounds, namely carotenoids, which constitute several food 
products23,137. Carotenoids produced by microalgae can act on oxidative stress by diminishing free 
radicals and ROS, which have been pointed out as drivers of many human diseases88, such as 
Alzheimer, Parkinson and other neurological diseases, as well as cancer, among others88. β-
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carotene from Dunaliella salina is a well-known carotenoid produced by this marine microalgae, 
with antioxidant properties and hence used to remove free radicals88.  
 Marine macroalgae can normally be utilized as vegetables, medicines, fertilizers, and raw 
materials in different industries, given their anticancer, anticoagulant, and nutritional 
properties112. Natural products from these macro organisms include polysaccharides (e.g., from 
Rhodophyta), which can present anticoagulant properties by interfering with fibrin 
polymerization, what is usually essential for blood coagulation112. Included in the polysaccharides 
studied from macroalgae, fucoidans (from brown algae), carrageenan (from red algae) and ulvan 
(from green algae) can have significant roles in cancer control and have been investigated for that 
purpose138. 
2.1.4- Invertebrates and their symbionts 
 
Among the marine invertebrates, tunicates (phylum Chordata), cnidarians (phylum 
Cnidaria), and especially sponges (phylum Porifera)113 may produce a diverse classes of 
compounds, like terpenes, sterols, fatty acids, cyclic peptides, amino acid derivatives and 
alkaloids23. Some of the invertebrate-derived marine drugs have already been approved or are in 
tests phase. For example, aplidine (approved in March 2018) is a depsipeptide originally isolated 
from de tunicate Aplidium albicans121 that possess anticancer activity but it was removed from 
market in December 14th 2018 for its lack of activity range. Jorumycin is an alkaloid from the 
mollusc Jorunna funebris and has been applied in schizophrenia cases107. The marine sponge 
Oceanapia sp. produces the antibacterial C14 acetylenic acid that is a fatty acid and is effective 
against Escherichia coli, Pseudomonas aeruginosa, Bacillus subtillis and Staphyloccocus aureus132. 
From a sponge of the genus Leiodermatium was extracted leiodermatolide, a polyketide with 
antibiotic capacity that exhibits cytotoxicity against several pancreatic cancer cell lines, like AsPC-
1, PANC-1, BxPC-3 and MIA PaCa-2139.  
When it was realized that marine invertebrates harbour many bacterial symbionts, the 
source of bioactive compounds was thought to be also of bacterial origin. Tetrodotoxin is capable 
to treat neuropathic pain and is in phase III trials140. Nojirimycin, originally isolated from the 
sponge symbionts Streptomyces roseochromogenes and Streptomyces lavendulae, is a natural 
product abundantly used to fight type II diabetes141. Bacillus tequilensis isolated from the sponge 
Sarcotragus fasciculatus has β-glucosidase inhibitors also with anti-diabetic potential142. 
Pseudomonas piscicida from the sponge Hymeniacidon perleve has Norharman (from β-carbolins 
compound class) with anti-microbial activity143. Some compounds with anti-tumorigenic potential 
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like Yondelis® (drug approved in 2007 in Europe by the European Medicines Agency) can be used 
in the treatment of ovarian and breast cancers, melanomas, soft tissue sarcomas, being extracted 
from bacterial symbionts of marine invertebrates144.  
Similarly to sponges, the cnidarians are also quite distributed in seas and oceans 
worldwide145,146. They possess specialized cells (cnidocytes) that are used to kill preys for feeding 
purposes, as well as to guarantee their defence and movement147. The phylum Cnidaria is divided 
into Anthozoa that includes sea anemones and corals, and Medusozoa, which includes classes like 
Staurozoa, Hydrozoa, Schyphozoa and Cubozoa112. Hydrozoan species can host bacteria as part of 
their tissues148. The symbiotic bacterial community is specific, for example, of each Hydra species 
(a well-known hydrozoan) and their endoderm is structured as to fight bacterial pathogens 
through the production of antimicrobial peptides, thereby constituting an alternative for the 
absence of a physical barrier149,150. In extracts of Hydra, Hydramacin-1 is a peptide obtained with 
high antimicrobial activity145. This peptide seems to be enhanced by other microbial products, like 
lipopolysaccharides (LPS), which have antibacterial activity against Bacillus megaterium, 
Escherichia coli, Klebsiella oxytoca and Klebsiella pneumoniae strains, but barely shows activity 
against Pseudomonas aeruginosa145. Regarding medusozoans, jellyfish like Pelagia notiluca have 
also been approached in some studies focusing on the isolation of compounds151. Moreover, a 
symbiont isolated from the jellyfish Cyanea capillata belonging to Pseudomonas sp. genus, could 
synthesize the antimicrobial protein CAP-1 that is highly inhibitory of the growth of marine 
pathogenic microorganisms like Vibrio vulnificus152. CAP-1, however, is not cytotoxic to human 
tumoural and normal cells of the skin152. Notwithstanding, this bioactive potential should be 
further analysed against other targets and applications.  
 
3- Objectives and structure  
 
              This work had two major objectives. One of them intended to perform the state-of-the-art 
regarding pancreatic cancer, as well as its main therapeutic approaches and gaps that can be 
potentially fulfilled by the discovery of new bioactive natural compounds produced through 
specific biosynthetic pathways, especially occurring in living resources of the marine environment. 
The other aim is to unravel the potential of bacterial symbionts isolated from marine cnidarians to 
synthesize bioactive compounds against PDAC. In order to accomplish these goals, the following 
specific objectives were established: 
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● to make a literature review on pancreaƟc cancer eƟology, epidemiology, diagnosis, biology, 
carcinogenesis and current treatments, as well as on the discovery of novel natural products, 
especially from the marine environment; 
● to summarize the biosynthetic pathways sustained by NRPS and PKS, and the bacterially-
synthesized NRPs and PKs natural compounds; 
● to screen the potenƟal bioacƟvity of bacteria isolated from cnidarians sampled in the Atlantic 
Ocean, through the application of a molecular approach and testing of crude extracts against a 
pancreatic ductal adenocarcinoma cell line. 
 
 This document is thereby structured in chapters that are lined with these objectives, 
being some of the chapters organized in a paper-directed format: 
● Chapter I: General Introduction 
● Chapter II: NRPS, PKS and hybrid genes – structure, derived marine natural compounds, and 
genetic engineering 
● Chapter III: Screening of marine bacteria for the potential biosynthesis of NRPs bioactive 
compounds against pancreatic cancer 
● Chapter IV:  Final ConsideraƟons 
 
4- Scientific outputs during the MSc research 
 
Poster - Scientific poster entitled as “Potential of marine bacteria to synthesize bioactive 
compounds for medical application”. Authors: Mafalda Tabuada, Carlos Moura, Amadeu M.V.M. 
Soares, Catarina R. Marques. Poster presented at the IV Post-Grad Symposium in Biomedicine, 
ibiMed, UA. p. 59. 
 
Review/ research articles: 
Chapter I and II- A review paper will be prepared from the state-of-the art and literature search 
performed for the topics focused in chapters I and II. 
 
Chapter III- An original research paper will be submitted to the international peer-reviewed 
scientific journal Research in Microbiology, being the title: “Screening of marine bacteria for the 
potential biosynthesis of NRPS bioactive compounds”. 
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NRPS, PKS and hybrid genes – structure, derived marine natural 
compounds, and genetic engineering 
 
 
Abstract 
Nonribosomal peptides (NRPS), polyketide synthases (PKS) and NRPS/PKS hybrids are 
genes that became known for encoding huge and complex modular enzymes involved in the 
microbial synthesis of secondary metabolites. These secondary metabolites are natural products 
with important ecological and biological activities that may serve a broad use for medical and 
industrial purposes. According to their bioactivity or properties they may be antibiotics, 
siderophores, surfactants, anticancer substances, immunosuppressive and anti-inflammatory 
compounds. Given the relevance of these genes, the present chapter focus on PKS, NRPS and 
hybrids structure and biosynthesis, their occurrence in marine microbes, mediation of the 
biosynthesis of marine natural products, and on the main advancements with regard to the 
genetic engineering of those modular enzymes as producers of natural compounds derived from 
marine bacteria.  
 
 
Key-words: enzymes, nonribossomal peptides, polyketides, bioactive compounds, marine bacteria 
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 Structure and biosynthesis of NRPS and PKS enzymes 
 
 
The nonribosomal peptide synthetases (NRPS) and polyketides synthases (PKS) are 
multimodular enzymes with remarkable structural diversity that sustain the biosynthesis of many 
secondary metabolites or natural products, broadly referred as nonribosomal peptides (NRPs) and 
polyketides (PKs), respectively. The NRPs- and PKs-encoding genes and genetic machinery are 
hence frequently found in the three domains of life represented by Bacteria, Archaea and 
Eukarya153.  
Overall, their biosynthetic pathways rely on sequential metabolic steps mediated by each 
module of NRPS or PKS enzymes, which resulting organization of the monomers in the 
compounds produced depend on the organization of the modules composing the enzymes154. The 
chemical structural unit (or monomers) incorporated by NRPS and PKS modules is an aminoacid 
(for peptide synthesis) or a carboxylic acid (e.g., for fatty acid synthesis where monomers are acyl-
CoA), respectively155. The great variability and arrangement of the enzymes modules and, 
consequently, of the monomers and their combinations, definitely contribute to the wide 
diversity of NRPs and PKs compounds, in terms of size and chemical structure120. Indeed, such 
diverse chemical structures of NRPS- and PKS-based products, coupled to the possibility of 
interacting with different (bio)molecular targets/receptors, provides a wide range of bioactivities 
relevant for different applications156. A major relevance of these compounds is that they may 
present a variety of biological activities with high pharmaceutical interest157, besides other 
properties relevant for other applications158.  
The number of NRPS modules (or catalytic units) depend on the number of aminoacids to 
be synthesized, but each one can be divided into three major domains: (i) the adenylation (A) 
domain with properties that allow the identification and activation of certain amino acid residues 
which are then transported to the second domain; (ii) the peptidyl carrier protein (PCP) (or 
thiolation domain); (iii) the condensation domain (C) that catalyzes the formation of C-N bonds for 
the binding of the aminoacid to the elongated oligopeptide, and transport this oligopeptide to the 
next module158–160 (Fig. 1a). The termination module contains a thioesterase (TE) domain 
responsible for the release of the peptide/protein via hydrolysis or cyclization118,119,154,161,162. 
Additional domains can be present in each module of NRPS enzymes that catalyse aminoacids 
epimerization, reduction, oxidation, methylation (Fig. 1a). As such, each module add one 
monomer to the elongated oligopeptide chain, until being synthesized the final peptide/protein 
(Fig. 1a).  
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Although NRPS is normally referred as modular enzymes, 10% of bacteria gene clusters 
were found to codify nonmodular enzymes, what was associated with an evolutionary trend 
mediated by horizontal gene transfer153. Nonmodular enzymes are not organized in modules, but 
in catalytic domains which codify separate proteins. Nonmodular NRPS occur in biosynthetic 
pathways of siderophores, such as those peptides synthesized from adenylation (EntE, VibE) or 
condensation (VibH) domains respectively in enterobactin and vibriobactin biosynthetic 
pathways163,164. Natural products synthesized by NRPS can be arranged according to their 
biological activities. Different NRPS-derived products have antibiotic and antifungal activities, like 
tyrocidine, bacitracin, surfactin, vancomycin, fengycin, telomycin, griselimycin, nannocystin A165 
(Table 1). Lipopeptides are amphiphilic compounds, such as the surfactin produced by Bacillus 
subtilis, which can easily penetrate the microbial cell membrane and cause its disruption, thereby 
facilitating its use as an antimicrobial166. Cyclic peptides like nannocystin A have a huge 
antiproliferative and antitumor activity, targeting the translation factor 1 of eukaryotic cells167. 
The cyclic depsipeptide griselimycin was proved to possess strong activity against Mycobacterium 
tuberculosis168–170.  
PKSs are subdivided into three groups, type I, type II and type III, according to the 
structure of the modular enzyme. Type I PKS modular enzymes, however, are the most known 
and represented in the microbial secondary metabolism171. They consist of multi-enzyme 
complexes derived from various functional catalytic units or domains in each module (as 
explained above)158. Type I-PKS can yet be divided into interactive (one sole organized module 
that is iteratively synthesized until the final peptide; e.g., erythromycin172) or modular (different 
modules, i.e., each module corresponding to different set of domains are subsequently 
synthesized up to the final peptide; e.g., lovastatin172) enzymes (Fig. 1b). Similarly to NRPS, the 
type I PKS modules contain three domains: (i) acetyltransferase (AT); (ii) ketosynthase (KS); and 
(iii) acyl carrier protein (ACP). These domains are essential for PKS elongation. The AT domain 
adds the monomers malonyl or methylmalonyl-CoA. The KS unit is responsible for the C-C binding 
and linkage of the building blocks to the oligopeptide chain. The ACP domain is similar to the PCP 
domain in NRPS, and works as a support for the synthesis of PKS by promoting a covalent binding 
of the elongated chain of monomers158 (Fig. 1b). Alternative domains suchlike ketoreductase (KR), 
dehydratase (DH), enoyl reductase (ER), and methyltransferase (MT) may also be organized into 
PKS modules173 (Fig. 1b). Type I PKSs are responsible for the biosynthesis of complex and short 
polyketides like macrolides, polyether and polyenes169,170,174 (Table 1). The Type II PKS are mono- 
or bifunctional enzymes composing a stable complex175. They have a unique characteristic that is 
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their high amino acid sequence homology and highly conserved gene sequences176. This type of 
PKSs in bacteria produce aromatic polyketides, like oxytetracycline and pradimicin159. Type III PKS 
are small homodimer enzymes that have been more associated with the secondary metabolism of 
plants, though also identified in some bacteria. Among the compounds they produce there are 
chalcones, pyrones, acridones, phloroglucinols, stilbenes, and resorcinolic lipids157. 
Fig.1a: Example of the modular organization in NRPS, with adenylation (A), peptidyl carrier protein (PCP), 
epimerization (E), N-methylation (M) and termination (TE) domains118,119,154,161,162 
Figure 1b: Example of the modular organization of type I PKS modules, with adenyl-transferase (AT), ayl 
carrier protein (ACP), ketosynthase (KS), dehydratase (DH), enoylreductase (ER), ketoreductase (KR) and 
termination (TE) domains173. 
 
The combination of PKS and NRPS in a biosynthetic cluster, leads to the synthesis of 
PK/NRP hybrids. This type of compounds can be broadly divided into two classes according to 
their synthesis. One includes the hybrids that are separately synthesized by NRPS and PKS 
enzymes, and afterwards combined into a final hybrid compound. The other class involves the 
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Examples of compounds Chemical class/structure
Surfactin Cyclic l ipopeptide
Tyrocidine Cyclic decapeptides Anticancer
Vancomycin Glycosylated peptide Antibiotic
Fengycin Lipopetide Antibiotic
Bacitracin Cyclic peptide
Telomycin Lipopetide Antibiotic
Nannocystin A Macrolactone peptide Anticancer
Griselimycin Cyclic peptide Antibiotic
Erythromycin Macrolides
type I Nanchangmycin, monensin, nigericin, tetronomycin Polyethers Antifungal, phytotoxic
Rapamycin Polyenes
type II Lipopetide biosurfactants Antimicrobial, antibiofi lm
Glicopeptide biosurfactants Antimicrobial
Various polyketides Aromatic polyketides
C21 heptaketide Chalcones Antibiotic
type III Salinipyrone A Pyrones Anticancer
Triazoleacridone Acridones Anticancer
C18 heptaketide Phloroglucinol
Equisetin, Pseurotin A Tetramic acids Antifungal, neurogenic
Enzymes
NRPS
NRPS/PKS 
hybrids
PKS
Antithrombotic, profibrinolytic, anticoagulant
Anti-inflammatory, antioxidant
Antifungal, anticancer, immunosuppressive
Antibiotic, antifungal , anticancer
Antibiotic, antifungal
Antibiotic, antifungal , antiviral, hemolytic
Activities
Biosurfactants
peptide-polyketide products that are directly synthesized from the functionally combined NRPS 
and PKS enzymes177 (Table 1).   
 
Table 1: Examples of bioactive compounds associated with NRPS, PKS and NRPS/PKS hybrids. 
 
Marine environment as a pool of PKS/NRPS genes 
 
Marine natural products have been isolated and identified from different marine 
organisms like macroalgae, sponges, tunicates143. However, several studies have been focusing on 
the potential of microbial symbionts that live in association with marine invertebrates towards 
the production of bioactive secondary metabolites193. One of the strategies followed for the 
discovery of new natural products is based on the culture of microorganisms and screening of 
their bioactive potential. But with the onset of next generation (sequencing) tools together with 
the revolution of bioinformatics tools, other frameworks have been conducted, which reveal a 
diversity of silent gene clusters in marine microbes that potentially encode a tremendous range of 
bioactive metabolites159 These molecular- and genetic-based technologies help to overcome 
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culture difficulties, while simultaneously help to uncover the hidden biosynthetic potential in 
marine (microbial) resources. Notwithstanding the natural synthesis and isolation of the 
compounds are limited or compromised if the microorganisms are uncultured. As such, other 
studies performed the bioprospection of microbes biosynthetic abilities through a preliminary 
molecular screening, before going into the application of compounds extraction procedures153. 
For instance, sequencing and genome mining techniques has been used to identify biosynthetic 
gene clusters encoding NRPS, PKS and NRPS-PKS hybrids in the genomes of marine bacteria, such 
as Gram-negative representatives of the Alpha- and Gammaproteobacteria clades194. Vibrio, 
Roseobacter and Pseudoalteromonas evidenced several bioactive metabolites capable of inducing 
chitinolytic, iron quenching (siderophore production) and/or quorum sensing properties111,195 
Brito et al.155, started by doing a molecular screening of the genes encoding NRPS and PKS 
enzymes in marine cyanobacteria isolated from the Portuguese coastline (Atlantic Ocean). The 
authors found a greater presence of PKS genes than NRPS. Moreover, some cyanobacteria could 
synthesize natural compounds (analogues of known and unknown compounds; e.g., antanapeptin 
C, dolastatin 16, malyngamides cluster, and cyanotoxins as nodularin and microcystin) under 
laboratorial conditions, as determined by LC-MS and molecular networking. The metabolite 
barbamide was also isolated from a marine cyanobacteria (Lyngbya majuscula), which 
biosynthetic gene cluster (bar) encodes a hybrid PKS-NRPS enzymatic system184,198,199. 
Furthermore, it encompasses unusual aspects, specifically, the A and PCP domains of NRPS for 
leucine/trichloro leucine are encoded in separated open reading frames198, and the PKS module of 
this cluster is split into two proteins (BarE/BarF)200. Although there is a co-linear arrangement of 
PKS-NRPS systems, the produced natural compounds are constrained by complex protein-protein 
interactions185. NRPS and PKS genes in marine microbes have been frequently detected in 
bacterial representatives of Proteobacteria, Actinobacteria, Firmicutes and Cyanobacteria, and in 
Ascomycota fungi153. Marine Actinobacteria, in particular, enclose a vast pool of unexplored 
bioactive products. For instance, Salinispora tropica evidenced a complex metabolome of 
secondary metabolites201. Later on, it was concluded that it can produce natural compounds 
(salinosporamide A and B) through a hybrid PKS-NRPS pathway using the building blocks acetate, 
β-hydroxy-2’-cyclohexenylalanine, and either butyrate or a tetrose-derived chlorinated molecule. 
These compounds present various activities, namely anti-cancer activity196,197,202,203. 
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Biotechnological applications and genetic engineering of PKS/NRPS 
 
Although the culture of bacteria for natural products bioprospection is a valuable 
biotechnological avenue, it may bring some limitations if their production at large scale is 
intended. One major limitation concerns bacteria domestication, which may gradually lead to the 
reduction of NRPs and PKs gene expression and synthesis, as far as laboratorial culture conditions 
fail to reproduce environmental conditions that promote the expression of an adaptive secondary 
metabolism109. Furthermore, the chemical structures of naturally-obtained compounds may not 
be biocompatible or provide a stable activity, especially if a pharmacological application is 
required. However, the determination of NRPS, PKS and hybrids genetic diversity and machinery, 
the chemical structure of the assembled compounds, mechanistic/enzymatic pathways, and 
networks, can provide information for the generation of new chemicals, through the application 
of genetic engineering tools118,204.  
The engineering of PKS-NRPS hybrids may take advantage of the natural diverse chemical 
structures/compositions of the compounds, in order to produce new customized chemicals that 
may be difficult to obtain through artificial chemical synthesis205–207. NRPS can be indeed 
engineered to achieve optimized natural products with enhanced bioactivity, and help with 
pharmaceutical needs to fight different diseases204. As such, NRPS gene clusters were already re-
designed. A first attempt was made on surfactin synthetase, being the natural A-PCP domains 
(responsible for leucine addition) replaced by others of bacterial and fungal origin208. The 
haemolytic capacity of the altered surfactin was kept, though peptide production was not greatly 
increased. The discovery of gene sequences encoding a link (composed by aminoacids with no 
particular function) between NRPS domains allowed their exploitation for engineering enzymatic 
fusions without losing the integrity/activity of enzymes209. Also, the engineering of NRPS A 
domain-specificity by the introduction of site-mutations of substrate amino acids, provides an 
option for the manipulation of NRPS biosynthetic clusters towards the creation of new 
antibiotics126. 
Another strategy that has been exploited for the controlled biosynthesis of new 
compounds relies on the heterologous expression of NRPS, PKS or NRPS-PKS hybrid gene clusters, 
either identified via metagenome analysis or previously engineered209, by bacterial vectors like 
Streptomyces, which genetic machinery may be tailored to overexpress and produce the 
compounds210. Streptomyces toyocaensis NRRL 15009, which is the producer of the non-
glycosylated “glycopeptide” A47934, is an expression vector capable of synthesizing hybrid 
glycopeptide antibiotics211,212. Genome mining of this species revealed its reduced size, and the 
Chapter II – NRPS & PKS genes 
 
26 
 
presence of only four NRPS, one type II PKS and none type I PKS gene clusters. These genetic 
features highlight the value of S. toyocaensis NRRL 15009 for the heterologous expression of 
cryptic NRPS gene clusters213. Awakawa et al.185 also re-designed the biosynthesis of modular 
NRPS/PKS hybrids producing the antimycins JBIR-06 (tri-lactone) and neoantimycin (tetra-lactone) 
through heterologous expression, hence resulting in novel antimycin analogues. These 
approaches mostly consider the modular organization and structure of the chemicals synthesized 
by particular Actinomycetes, but it requires their validation in other bacterial systems (e.g., 
marine-derived species) and their respective NRPS/PKS assemblies193. Other example was the 
engineering of Streptomyces avermitilis (synthesizes avermectin) and Saccharopolyspora 
erythraea (synthesizes erythromycin) PKSs to produce spinosyn derivatives. The specificities of 
erythromycin and avermectin loading modules allowed the generation of hybrid PKs, which once 
replaced by the spinosyn loading module lead to the production of novel spinosyn analogues with 
new and/or enhanced activity for insect control202,214. Hence the modular organization of 
erythromycin and avermectin PKS provided the means to employ genetic engineering and custom 
the chemical structures of their products in a targeted way.  
Thus, the success of biosynthetic engineering approaches in the production of a wide 
range of novel compounds has been accomplished. Therefore, the creation of optimized novel 
compounds, not known in nature, is likely to soon assume a breakthrough in biotechnology and a 
major relevance in clinics, as well as other sectors (e.g., industry).  
 
Conclusions 
 
The complex modular enzymes PKS, NRPS and PKS-NRPS hybrids are ubiquitously and 
diversely catalysing the synthesis of natural polyketides, peptides or polyketide-peptide 
compounds, respectively, by microbes from different environments. The marine environment, 
however, is believed to harbour a large pool of yet unknown biosynthetic microorganisms. As 
such, a great effort has been lately devoted to the search of novel marine compounds that could 
help with the lack of therapeutics for different diseases (e.g., bacterial infections, cancer) or drugs 
to control multi-resistant bacteria, as well as with the need of compounds to serve different 
industrial, agricultural or environmental processes/services. As the laboratorial culture of 
microbes may present several limitations to mimic the environmental traits stimulating the 
production of PKs, NRPs and hybrid compounds, new approaches have been searching towards 
their large and controlled production for different (bio)technological applications. In this context, 
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genetic engineering together with next-generation sequencing and bioinformatics tools is 
contributing to the re-design of the naturally-occurring enzymes/compounds and biosynthetic 
pathways. Consequently, new compounds or analogues have been generated with optimized 
structures, stability and enhanced activities, tailoring new opportunities for supplying 
environmental, technological and social requirements.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter III 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter III- NRPS screening 
 
31 
 
Screening of marine bacteria for the potential biosynthesis of NRPs 
bioactive compounds against pancreatic cancer  
 
Abstract 
 
The high malignancy of pancreatic cancer together with the severe limitations of the 
currently available treatments, namely involving drug resistance and inefficacy, the search for 
new anticancer drugs from natural sources has been claimed. Natural products that can modulate 
multidrug resistance have characteristics such as lower toxicity due to potentially high tumour 
selectivity, which may offer attractive opportunities. Therefore, the aim of this work is to apply a 
molecular approach to screen for the biosynthetic genetic potential, as well as, the bioactivity of 
crude extracts of marine bacterial symbionts isolated from cnidarians. Among the strains tested, 
in 39 was amplified a conserved region of the nonribosomal peptide synthetase (NRPS) A 
domaingenes. These bacteria were mainly assigned to the Proteobacteria and Actinobacteria 
phyla. Fourteen were selected given their ease of culture and the success on NRPS gene 
fragments amplification. The greatest part of them proved to harbour genes of NRPS biosynthetic 
cluster with high homology, and the crude extracts (cell and cell-free fractions) were generally 
cytotoxic to Capan-1 human pancreatic ductal adenocarcinoma cell line, as indicated by the MTT 
assay. The results were promising and gave the confirmation of association between the presence 
of NRPS in marine bacteria and potential production of bioactive compounds with anti-cancer 
activity.  
 
 
Key-words: molecular screening, biosynthetic gene, crude extracts, bacterial symbionts, 
cnidarians, pancreatic ductal adenocarcinoma, MTT assay 
 
Introduction 
 
Although pancreatic ductal adenocarcinoma (PDAC) is ranked in the 7th position among 
the deadly cancers in the world1, it is a quite threatening cancer given its silent and quick 
progression and metastization, low responsiveness to current therapeutics, high probability of 
recurrence after surgery, and a great ability to develop multidrug resistance. In order to cope with 
these clinical hurdles, some effort has been put towards the discovery of new drugs to fight PDAC.  
Natural products synthesized by living organisms can present anticancer bioactivity and 
simultaneously be less toxic than conventional chemotherapeutic drugs (e.g., gemcitabine), if 
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highly specific for targeting the tumour site. The testing of natural compounds against PDAC has 
been increasing, and several reports have been highlighting specific compounds capable of being 
used as potential adjuvant therapeutic drugs (e.g., curcumin and capsaicin)105,115 resents a 
thorough review on the natural compounds that have been tested in combination with current 
chemotherapeutic pharmaceuticals in preclinical and clinical trials, with the aim of controlling 
PDAC progression.  
Microbes, and bacteria in particular, can be promising producers of anticancer natural 
compounds, once many of them evolved a secondary metabolism to sustain different biological 
and eco-physiological adaptations, which lead to the formation of metabolites with peculiar 
bioactivities with interest for medical applications, like cancer treatment215. Under this context, 
marine bacteria and bacterial symbionts living in association with invertebrates are major sources 
of natural compounds, evidencing a widely unknown resistome205 and metabolome217. Hence, the 
sequenced environmental microbial genomes so far had revealed that a potential diversity of 
novel bioactive compounds exists207,218,219, what broadens the horizons regarding new compounds 
discovery. among the chemical classes of compounds lately explored, nonribsomal peptides 
(NRPs) synthesized through the action of modular and multifunctional enzymes broadly named as 
nonribsomal peptides synthetases (NRPS), have been a great opportunity for the development of 
novel anticancer medicines, like bleomycin in preclinical trials and primarily isolated from 
Streptomyces verticillus220. The multiple modules and domains composing the modular NRPS 
enzymes, as well as the diversity of the genetic machinery and biosynthetic gene clusters 
encoding NRPS194, renders an enhanced relevance given the diverse chemical structures and 
activities that can consequently arise156,209,221. Deep-sea marine bacterial strains, symbionts of 
sponges, tunicates or cnidarians and been evidencing a genome enriched in NRPS clusters126,222. 
Moreover, bacteria from different phyla well known to produce secondary metabolites, especially 
Actinobacteria, have been screened for NRPS gene clusters117, and the possible products 
associated to NRPS sequences have also been predicted145. According to a study, marine 
actinomycetes that potentially synthesize anti-cancer compounds possess a certain diversity of 
NRPS gene clusters210. Notwithstanding, many bioactive compounds produced by marine bacteria 
are related to a combined activity of both NRPS and polyketides, as the hybrid compounds can 
offer enhanced and more specific activities223. Despite the great discoveries that have been 
reached and efforts to unravel new anticancer natural drugs, the marine environments are still 
greatly overlooked and underrated122. Multiple marine ecological niches yet to be screened 
enclose promising genetic and biosynthetic diversities with potential relevance to fight PDAC. 
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Thereby, the aim of this work is to screen for the biosynthetic potential of marine bacteria 
isolated from cnidarian species through the use of molecular techniques directed to the 
amplification of NRPS gene fragments. Furthermore, in a way to confirm the production and 
activity of compounds produced by the NRPS-harbouring marine bacteria, their crude extracts 
were tested against a human PDAC cell line.  
 
Materials and Methods 
Bacterial symbionts, culture and storage conditions 
 
The bacterial strains used in this study were previously isolated from nine cnidarian 
individuals, which were sampled in the Atlantic Ocean. The bacterial isolates were individually 
grown in marine agar plates at room temperature (20 ± 2ºC), being stored every time needed in 
15% glycerol at -80ºC.   
Molecular screening of NRPS gene fragments 
 
 In order to identify the potential of bacterial isolates to synthesize bioactive secondary 
metabolites, the presence of genes encoding NRPS were screened through polymerase chain 
reaction (PCR). For that, a set of degenerate primers targeting conserved genetic regions of the 
adenylation domain (A) of NRPS was used. A total of 175 bacterial strains isolated from all the 
cnidarians hosts were subjected to this molecular screening approach. Before PCR, bacterial 
genomic DNA (gDNA) was extracted by heat lysis at 105ºC during 5 minutes in a dry bath, 
followed by a cooling step at 4ºC for at least 15 minutes. The NRPS genes were PCR-amplified 
from bacterial gDNA using the degenerate primers A2F (5’-AAGGCNGGCGSBGCSTAYSTGCC-3’) and 
A3R (5’TTGGGBIKBCCGGTSGINCCSGAGGTG-3’). Reactions for NRPS were performed in a final 
volume of 25 µL containing ca. 20 ng of gDNA, 400 pmol of each primer and 12.5 µL of Dream Taq 
Master Mix. The PCR run was conducted in a C-1000 Touch™ Thermal cycler from Bio-Rad, 
according to the next profile for NRPS: 4 min at 95°C, and 30 cycles 1 min at 95°C, 1 min at 70°C 
and 1 min at 72°C, followed by 10 min at 72°C. It was applied an agarose gel electrophoresis (CS-
300V, Frilabo) for the separation of the PCR products in a 1% agarose gel. The amplicons were 
then observed in an UV Transilluminator Chemidoc XRS+ (Bio-Rad). The PCR amplicons were 
purified with a PCR-product purification kit and sequenced. The nucleotidic sequences were 
converted into aminoacid sequences and compared with available protein databases in BlastP®. 
The annotation was performed based in NCBI non-redundant protein database. Bacterial strains 
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that did not present culture constraints and for which was possible to get high amplification of the 
A domain-encoding amplicons, were selected for the preparation of crude extracts. 
Bacterial identification through 16S rRNA gene sequencing 
 
The 16S rDNA gene was amplified from gDNA (extracted as previously described) through 
the primers 27F (5’-AGAGTTTGATCCTGGCTCAG-3’) and 1522R (5’-AAGGAGGTGATCCAGCC-3’) 224. 
Reactions for 16S were performed with the Dream Taq Master Mix for a final volume of 25 µL 
containing ca. 20 ng of gDNA and 0.3 µM of each primer. The PCR run was conducted for 9 min at 
94°C, followed by 29 cycles of 30s at 94°C, 30s at 56°C and 90s at 72°C, and a final elongation step 
of 10 min at 72°C. The 16S amplicons were separated in an electrophoresis (see above), being the 
corresponding band excised from the gel, purified with a DNA purification kit, and subjected to 
Sanger sequencing. The nucleotide sequences were compared with NCBI database entries using 
BlastN® program. 
Preparation of bacteria crude extracts 
 
The bacteria previously selected (i.e., presenting an intense band of A-domain amplicons) 
were grown in Marine broth at 23ºC up to the stationary phase. The obtained bacterial 
suspension was centrifuged to separate cells from the supernatant, thereby obtaining cell and 
cell-free fractions, which were extracted with acetone (2:1) and ethyl acetate (1:1), respectively. 
After incubation with agitation, the solvent layer of cell and cell-free fractions were separated and 
evaporated in a BÜCHI rotary evaporator at 40ºC. The dried crude extracts were weighted, 
dissolved in DMSO and stored in aliquots at -20ºC.  
 
 
 
 
 
 
 
 
Fig.2: Representation of the metabolite extraction process with A) decantation, B) evaporation and C) 
obtained extract. 
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Cancer cell line culture and MTT assay 
 
The human PDAC cell line Capan-1 was cultivated in RPMI medium supplemented with 
FBS 10% and maintained at 37ºC and 5% CO2, being used for the assays at ca. 70% confluence. 
The prepared crude extracts from both bacterial fractions were tested for their cytotoxicity 
against Capan-1 cells through the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium 
bromide] colorimetric assay. This functional assay allows determining the impact of the extracts 
on the activity of mitochondrial enzymes, which catalyse the reduction of MTT to formazan, 
hence forming violet crystals that can be spectrophotometrically measured225 at 550-590 nm. 
Before performing the assay with the bacterial extracts, the conditions for running it were 
optimized in regard to: (i) initial cell density (1x103, 5x103, 1x104 and 5x104 cell/mL); (ii) DMSO 
concentration [0%, 0.5%, 0.8%, 1% and 2% (v/v)] since extracts were dissolved in DMSO, (iii) 
measuring times after dissolution of formazan crystals (5 min, 10 min and 15 min after adding the 
solvent to dissolve formazan crystals), (iv) measured wavelengths (500, 540, 570, 590, 650 nm). 
From a 70% confluent cell culture was prepared a cell suspension, which cell density was counted 
in a Neubauer chamber. The different cell densities were prepared in RPMI medium added with 
FBS and dispensed in the respective 96-well cell culture microplates, for cells attachment during 
approximately 24h (see culture conditions above). Then the culture medium was removed and 
replaced my DMSO-containing medium (200 µL) at the appropriate concentrations. Four 
experimental replicates were considered per cell density and DMSO concentration, being empty 
wells used as a blank. After 24h exposure under the same culture conditions, the MTT assay was 
initiated for about 2-3h. At the end of this exposure time, the MTT solution was discarded and the 
formazan crystals were dissolved with concentrated DMSO. After 5, 10 and 15 min was measured 
the optical density at 500, 540, 570, 590 and 650 nm, being the latter used to correct any 
potential effect associated with turbidity that should not be accounted for the measurement of 
the biological parameter. 
At the light of the optimization outcome, the cytotoxicity assay performed with the crude 
extracts (cell and cell-free fractions) was performed with 1% of extract per well, and an increased 
initial cell density of 7x104 cell/mL due to the low absorbances obtained with 5x104 cell/mL. In this 
assay were also included: a blank, a negative control (cells + culture medium) and a solvent 
control (cells + culture medium with 1% DMSO). For each treatment (i.e., controls and extracts) 
were tested four technical replicates (i.e., 4 wells) and two experimental replicates (i.e., 2 
microplates). Cell seeding, attachment time, duration and conditions of exposure to bacterial 
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extracts was performed as for the optimization assays. The spectrophotometric measurements 
were made after 5 min dissolution at 570 nm and 650 nm.  
To the spectrophotometric readings was removed the absorbances obtained in the blank 
and at 650 nm. After this treatment, the average and standard deviation of the four technical 
replicates and the two experimental replicates were computed and depicted in charts. A one-way 
analysis of variances (ANOVA) followed by the post-hoc multicomparison Dunnett’s test were 
applied to detect statistically significant differences on cells viability exposed to DMSO 
concentrations or bacterial extracts in relation to that of the control (α = 0.05). Statistical analyses 
were performed in SigmaPlot® v14 software.  
 
Results and discussion 
 
On the search for novel biomedical drugs from marine bacteria, besides getting 
knowledge on their potential biosynthetic abilities (e.g., by genome mining) it is also relevant to 
realize if they are actually expressed. For that, the isolation and culture of the bacteria can be a 
crucial step to explore the production of natural compounds and get more information on the 
biosynthetic bacteria (e.g., taxonomic identification). In this context, it was followed a molecular 
strategy for detecting the presence of NRPS-encoding genes in the gDNA of the marine bacterial 
strains isolated from cnidarian species193.  
 
Detection of NRPS A domain  
 
From the screening of 175 bacterial strains for NRPS gene fragments presence, 39 were 
positive (=22%) (Table 2). This value is approximate to those reported in other studies focusing on 
bacteria from marine sediments (30% of positives)158 or from sea sponges (with 13% positives)219. 
These percentages are however a rough and very relative estimation that depend on much factors 
like the ecological niche and environmental conditions, extraction and isolation methods, primers 
used and gene sequences targeted. Indeed, some studies got much higher percentage of NRPS-
positive bacteria (63%) from marine sediments117. However, none of the mentioned studies 
developed this type of screening in bacteria isolated from cnidarians, what represents a promising 
and pioneer outcome towards the possibility of prospecting bioactive compounds. 
All cnidarians had symbionts harbouring NRPS genes, although the number of NRPS-
positive bacteria from each host is not very uniform along the cnidarian individuals, which can be  
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Fig.3: Percentage of bacteria presenting NRPS gene fragments in each group of cnidarians considered.  
 
 
ranked by decreasing order as CN2 > CN3 > CN9 > CN5/CN8 > CN6 > CN1 > CN7 (Fig. 3). CN4 
(Tables 2 and 3; not plotted) presented 100% percentage of bacteria potentially producing 
bioactive compounds, however this group only possessed one bacterial clone. This outcome is in 
line with the potential production of NRPs by symbionts of different cnidarians. A jellyfish 
symbiont, Pseudomonas sp., was found to be a producer of CAP-1 protein, an antimicrobial 
compound that has also the capacity to inhibit several marine microorganisms like pathogenic 
Vibrio species152. Soft-corals have also been found to contribute to a new source of antibiotics 
based on the presence of NRPS genes in bacterial symbionts (e.g., Pseudomonas sp.), which are 
not harmful for the host, but in turn have activity against Streptococcus equi226. Some beneficial 
symbiotic microbes have indeed proved to produce antifungal compounds in the tissue surface of 
hydrozoan species149. In cnidarians like Aglaophenia sp., Vibrio species can have an important 
ecological role to this type of  organisms227, and in the present study, Vibrio spp. were identified in 
CN3, CN6 and CN9 cnidarians. Obelia sp. have the capacity to gather bacteria in their gastric 
cavity228. Bacteria makes part of Obelia “diet”, while they filtrate them to their stomach cavity and 
use them as bacteriophages228. In the present study, Pseudomonas spp. are well represented in 
CN2, CN4 and CN7 cnidarian groups with four different species, namely Pseudomonas alcaliphila 
in CN7 group (Table 3) that has the capacity of biodegrading bile acids and use them as a carbon 
source229.   
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Clones NRPS Clones NRPS Clones NRPS Clones NRPS Clones NRPS Clones NRPS Clones NRPS Clones NRPS Clones NRPS Clones NRPS Clones NRPS Clones NRPS
M85 (+) M58 (+) M1 (-) M157 (+) M130 (-) M154 (-) M99 (-) M123 (+) M25 (-) M49 (-) M158 (-) M70 (-)
M86 (-) M59 (-) M2 (-) M131 (-) M155 (-) M100 (-) M124 (-) M26 (-) M50 (-) M159 (+) M71 (+)
M87 (-) M60 (+) M3 (-) M132 (-) M156 (-) M101 (+) M125 (+) M27 (-) M51 (+) M160 (-) M72 (+)
M88 (-) M61 (+) M4 (-) M133 (+) M102 (-) M126 (-) M28 (-) M52 (-) M161 (-) M73 (-)
M89 (-) M62 (-) M5 (+) M134 (-) M103 (-) M127 (-) M29 (-) M53 (+) M162 (-) M74 (-)
M90 (-) M63 (-) M6 (+) M135 (-) M104 (-) M128 (-) M30 (-) M54 (-) M163 (-) M75 (-)
M91 (-) M64 (-) M7 (-) M136 (-) M105 (-) M129 (+) M31 (-) M55 (-) M164 (-) M76 (-)
M92 (-) M65 (-) M8 (-) M137 (-) M106 (-) M32 (-) M56 (-) M165 (+) M77 (-)
M93 (-) M66 (-) M9 (-) M138 (+) M107 (-) M33 (-) M57 (-) M166 (-) M78 (-)
M94 (-) M67 (-) M10 (+) M139 (+) M108 (-) M34 (-) M167 (+) M79 (-)
M95 (+) M68 (+) M11 (-) M140 (-) M109 (-) M35 (-) M168 (-) M80 (+)
M96 (-) M69 (-) M12 (-) M141 (+) M110 (-) M36 (-) M169 (+) M81 (-)
M97 (-) M13 (-) M142 (-) M111 (-) M37 (-) M170 (-) M82 (+)
M98 (-) M14 (-) M143 (-) M112 (-) M38 (-) M171 (-) M83 (-)
M15 (+) M144 (-) M113 (-) M39 (-) M172 (-) M84 (-)
M16 (-) M145 (-) M114 (-) M40 (+) M173 (+)
M17 (-) M146 (+) M115 (+) M41 (-) M174 (-)
M18 (-) M147 (-) M116 (-) M42 (+) M175 (-)
M19 (+) M148 (-) M117 (-) M43 (-)
M20 (-) M149 (+) M118 (-) M44 (-)
M21 (+) M150 (-) M119 (-) M45 (-)
M22 (-) M151 (-) M120 (-) M46 (-)
M23 (+) M152 (-) M121 (+) M47 (-)
M24 (-) M153 (-) M122 (-) M48 (-)
CN4 CN8CN3CN2 CN9CN1 CN5 CN6 CN7
 
 
Table 2: Bacterial clones isolated and screened for NRPS gene fragments. (+) stands for the positive and (-) for the negative presence of the NRPS A domain gene 
fragment; CN# - cnidarian individual number (#); ns - not screened. 
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Identification of NRPS-positive bacteria 
 
For all the 16S rRNA gene sequences of the bacteria evidencing NRPS gene fragments, an 
homology between 81% and 99% was achieved (Table 3) to the closest relative in BLASTn. It has 
been defended that 98% is the limit below which two species are considered to be different, 
whilst below 95% may indicate it is a new species230. NRPS genes have been often found in the 
phyla Proteobacteria, Actinobacteria, Firmicutes and Cyanobacteria153,159. In the present study, it 
was possible to observe a distribution of the marine bacterial strains between the Proteobacteria 
and Actinobacteria phyla only (Table 3). Besides, Proteobacteria strains were assigned to 
Alphaproteobacteria or Gammaproteobacteria classes. The four principal genera observed among 
the NRPS gene fragments-harbouring strains were Ruegeria, Pseudomonas, Halomonas, 
Pseudoalteromonas and Vibrio. The remaining genera retrieved from the 16S rRNA sequencing 
analysis were Dietzia, Brachybacterium, Erythrobacter, Rhodococcus, Psychrobacter, Kribella, 
Pseudoalteromonas, Paracoccus, Sulfitobacter, Microbacterium, Brevibaterium, Cobetia and 
Alteromonas. This diversity is in accordance with currently available or consulted literature. The 
Vibrio and Pseudoalteromonas genera have been found to present NRPs- and NRP/PK hybrids-
encoding genes194. In the same study, the genus with most NRPS clusters was Pseudoalteromonas, 
which strains proved to have antibacterial activity194. In another study devoted to the screening of 
NRPS- and PKS-encoding  genes in marine bacteria living in symbiosis with invertebrates, the 
authors verified that Sulfitobacter, Paracoccus and Vibrio were among the potential biosynthetic 
strains221. It is also common to find Ruegeria and Pseudomonas representatives as producers of 
antimicrobial compounds (e.g., cyclic peptides) with proved activity against other bacteria121. 
Halomonas species were already reported to possess both PKS and NRPS genes231,232. 
Alteromonas, Sulfitobacter and Halomonas strains were proved to genetically carry and express at 
least one of the genes, and in the case of bacteria from Sulfitobacter and Halomonas genera 
showed to be able to induce high anticancer activity231. In relation to the other genera mentioned, 
the lack of bibliography suggests that they are poorly studied and highlight an unexplored 
resource for natural product discovery. 
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Cnidarian Clone Phylotype Closest relative phylotype in BlastN Class Phylum Homology (%)
M85 Rhodococcus yunnanensis Rhodococcus yunnanensis  YIM 70056 Actinobacteria Actinobacteria 96
M95 Psychrobacter celer Psychrobacter celer SW-238 Gammaproteobacteria Proteobacteria 93
M68 Rhodococcus cercidiphylli Rhodococcus cercidiphylli YIM 65003 Actinobacteria Actinobacteria 95
M60 Pseudomonas monteili Pseudomonas monteili  CIP 104883 Gammaproteobacteria Proteobacteria 98
M61 Pseudomonas monteili Pseudomonas monteili CIP 104883 Gammaproteobacteria Proteobacteria 97
M58 Alteromonas addita Alteromonas addita  R10SW13 Gammaproteobacteria Proteobacteria 98
M23 Vibrio gigantis Vibrio gigantis  LGP 13 Gammaproteobacteria Proteobacteria 98
M10 Ruegeria pelagia Ruegeria pelagia  NBRC 102038  Alphaproteobacteria Proteobacteria 99
M15 Ruegeria pelagia Ruegeria pelagia  NBRC 102038  Alphaproteobacteria Proteobacteria 97
M5 Ruegeria pelagia Ruegeria pelagia  NBRC 102038  Alphaproteobacteria Proteobacteria 96
M6 Dietzia maris Dietzia maris  AUCM A-593 Actinobacteria Actinobacteria 97
M21 Brachybacterium paraconglomeratum Brachybacterium paraconglomeratum  LMG 19861 Actinobacteria Actinobacteria 98
M19 Erythrobacter flavus Erythrobacter flavus  SW-46  Alphaproteobacteria Proteobacteria 96
CN4 M157 Pseudomonas plecoglossicida Pseudomonas plecoglossicida  FPC951 Gammaproteobacteria Proteobacteria 95
M146 Halomonas meridiana Halomonas meridiana DSM 5425 Gammaproteobacteria Proteobacteria 98
M149 Halomonas meridiana Halomonas meridiana  DSM 5425 Gammaproteobacteria Proteobacteria 97
M141 Halomonas meridiana Halomonas meridiana  DSM 5425 Gammaproteobacteria Proteobacteria 95
M139 Sulfitobacter faviae Sulfitobacter faviae  S5-53  Alphaproteobacteria Proteobacteria 81
M138 Rhodococcus yunnanensis Rhodococcus yunnanensis  YIM 70056 Actinobacteria Actinobacteria 97
M133 Halomonas denitrificans Halomonas denitrificans  M29 Gammaproteobacteria Proteobacteria 88
M115 Psychrobacter pacificensis Psychrobacter pacificensis NIBH P2K6 Gammaproteobacteria Proteobacteria 97
M101 Vibrio gigantis Vibrio gigantis  LGP 13 Gammaproteobacteria Proteobacteria 96
M123 Pseudoalteromonas flavipulchra Pseudoalteromonas flavipulchra  NCIMB 2033 Gammaproteobacteria Proteobacteria 97
M121 Pseudoalteromonas flavipulchra Pseudoalteromonas flavipulchra  NCIMB 2033 Gammaproteobacteria Proteobacteria 98
M125 Paracoccus rhizosphaerae Paracoccus rhizosphaerae  CC-CM 15-8  Alphaproteobacteria Proteobacteria 96
M129 Paracoccus haeundaensis Paracoccus haeundaensis  BC74171  Alphaproteobacteria Proteobacteria 98
M40 Pseudomonas chloritidismutans Pseudomonas chloritidismutans  AW-1 Gammaproteobacteria Proteobacteria 97
M51 Pseudomonas alcaliphila Pseudomonas alcaliphila  NBRC 102411 Gammaproteobacteria Proteobacteria 97
M42 Kribbella alba Kribbella alba  YIM 31075 Actinobacteria Actinobacteria 94
M53 Pseudoalteromonas paragorgicola Pseudoalteromonas paragorgicola  KMM 3548 Gammaproteobacteria Proteobacteria 95
M165 Cobetia amphilecti Cobetia amphilecti  46-2 Gammaproteobacteria Proteobacteria 97
M169 Brevibacterium permense Brevibacterium permense  VKM Ac-2280 Actinobacteria Actinobacteria 84
M173 Microbacterium oxydans Microbacterium oxydans DSM 20578 Actinobacteria Actinobacteria 93
M167 Sulfitobacter pontiacus Sulfitobacter pontiacus  ChLG-10  Alphaproteobacteria Proteobacteria 97
M159 Microbacterium hydrocarbonoxydans Microbacterium hydrocarbonoxydans BNP48 Actinobacteria Actinobacteria 97
M80 Vibrio gallaecicus Vibrio gallaecicus  Rd 8.15 Gammaproteobacteria Proteobacteria 94
M71 Vibrio gigantis Vibrio gigantis  LGP 13 Gammaproteobacteria Proteobacteria 95
M72 Ruegeria mobilis Ruegeria mobilis  NBRC 101030  Alphaproteobacteria Proteobacteria 98
M82 Ruegeria mobilis Ruegeria mobilis  NBRC 101030  Alphaproteobacteria Proteobacteria 97
CN8
CN9
CN1
CN2
CN3
CN5
CN6
CN7
 
Table 3: Outcome of the 16S rRNA gene sequencing analysis for the identification and homology of NRPS-
positive marine bacteria isolated from different cnidarian species. The light-green shaded clones 
correspond to the bacteria selected for further anticancer activity testing. Homologies ≤97% are 
represented in blue. 
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Analysis of NRPS A domain sequences 
 
Fourteen strains (cf. Tables 2, 3) with the best results on NRPS screening (band intensity) 
and ease of culture were selected for further study: M85, M60, M51, M139, M146, M61, M123, 
M157, M72, M125, M169, M15, M68 and M138. The primary step was to sequencing the 
amplicons of the NRPS A domain as to obtain the respective aminoacid sequences (Table 4). From 
the sequencing and analysis of the NRPS gene fragments only 8 amino acid consensus was 
obtained, which were related with NRPS, PKS or NRPS/PKS hybrid aminoacid sequences, 
previously determined in bacteria belonging to Pseudomonas, Pseudoalteromonas, Halomonas, 
Rhodococcus and Sulfitobacter genera (Table 4). These genera were coherent to the 16S rRNA 
identification obtained for the cnidarian bacterial symbionts herein studied (Table 3). The 
homology between the sequenced and BlastP-deposited aminoacid sequences ranged between 
37% and 96%, though it was broadly above 61%. These high similarities to NRPS peptides and/or A 
domain sequences are in agreement with the principal domain targeted by the degenerate 
primers used in the screening, hence reinforcing their reliability despite the known genetic 
diversity of NRPS genes233. Additionally, such diversity can be even more increased and become a 
quite valuable adaptation if NRPS/PKS hybrids occur. This might be the case of clone M157 that 
shows the genetic potential to synthesize a hybrid compound, which have been frequently 
suggested to be related with chemical scaffolds presenting enhanced bioactivity, 
complementarity to biological receptors, and stability122,126,234. Notwithstanding, considering that 
no reliable aminoacid sequence was obtained for 6 strains, either the sequencing of the amplified 
NRPS fragments should be repeated or other primers must be further tested. 
 
Bacteria crude extracts and MTT assay 
 
Although NRPS gene fragments sequencing demonstrated consensus only for 8 of the 
selected bacteria, the 14 bacteria selected according to the molecular screening were considered 
for the preparation of extracts from cell and cell-free fractions of grown cultures. A total of 28 
extracts were hence obtained. The concentrations of crude extracts varied between 2 and 22 
mg/mL DMSO for the cell fractions and between 3 and 25 mg/mL DMSO for the cell-free fractions 
(Table 5). These concentrations were considerably high considering that resulted from a 100 mL 
culture. 
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Strain Name Closest match in BlastP Similarity (%) Accession nr. Database
M85 Rhodococcus yunnanensis MULTISPECIES: non-ribosomal peptide synthetase [Rhodococcus ] 88 WP_094621983.1 nr
M60 Pseudomonas monteili Non-ribosomal peptide synthetase [Pseudomonas putida ] 96 WP_084850711.1 nr
M51 Pseudomonas alcaliphila
non-ribosomal peptide synthase 
domain TIGR01720/amino acid 
adenylation domain-containing 
protein, partial [Pseudomonas 
indica] 
66 SDK21005.1 nr
M139 Sulfitobacter faviae amino acid adenylation domain protein [Halomonas sp. KO116] 75 AJY51867.1 nr
RecName: Full=Polyketide synthase 
PksN 79 O31782.3 sw
amino acid adenylation domain 
protein [Halomonas sp. KO116] 82 AJY51867.1 nr
M61 Pseudomonas monteili non-ribosomal peptide synthetase, partial [Pseudomonas hunanensis] 85  PKF22537.1 nr
M123 Pseudoalteromonas flavipulchra 
RecName: Full=Nonribosomal 
peptide synthase atnA; AltName: 
Full=Aspercryptin biosynthesis 
cluster protein A 
37 Q5AUZ6.1 sw
M157 Pseudomonas plecoglossicida
non-ribosomal peptide 
synthase/polyketide synthase 
[Pseudomonas sp. p21] 
61 WP_063912751.1 nr
M146 Halomonas meridiana
Table 4: Prediction of correspondences for aminoacid sequences obtained from A domain of NRPS gene 
sequences to the selected bacterial strains (only sequences with reliable consensus are presented). 
 
 
        
 Table 5: Concentrations obtained of the crude extracts prepared. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clones Extracts from cell 
fractions  
[ ] (mg/ml DMSO) 
Extracts from cell-
free fractions 
[ ] (mg/ml DMSO) 
M51 2 20 
M157 20 10 
M61 13 11 
M85 10 3 
M139 10 10 
M72 20 20 
M68 20 20 
M146 10 20 
M60 20 20 
M125 20 20 
M169 20 20 
M138 9 25 
M15 22 20 
M123 20 20 
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For the MTT assays, a preliminary test was made in order to establish the optimal assay 
conditions (i.e., initial cell density, wavelength, and measuring time) and maximum DMSO 
concentration that did not affect Capan-1 cells growth. Figure 4 shows the cell viability response 
ranges of Capan-1 cell line in regard to different experimental variables that can influence the 
outcome of MTT assay. In general, a similar absorbance trend was obtained in the three reading 
times and wavelengths tested. As such, it was decided to set 5 minutes for formazan crystal 
dissolution and perform the absorbance readings at 570 nm. However, the initial cell density that 
provided better absorbance levels was 5x104 cells/mL, although still out of the recommended 
range (~0.75 – 1.25). Therefore, the MTT assay of the extracts was performed for an initial cell 
density of 7x104 cells/mL. The cytotoxic effect of DMSO was verified in order to evaluate which 
would be the maximum non-inhibiting concentration for the future testing of bacterial extracts, 
which were solubilized in DMSO. The cytotoxic effect of DMSO at different cell densities is shown 
in figure 5. In comparison to the control, significant inhibitory effects of DMSO occurred almost in 
all DMSO concentrations for cell densities equal or lower than 1x104 cells/mL, for all the 
wavelengths tested except at 500nm. In the 1x103 cells/mL cell density it can be verified that all 
the DMSO concentrations except 0.5% revealed to be toxic for Capan-1 cells. For the 5x104 
cells/mL cell density no significant cell viability inhibition occurred, except under 2% of DMSO at 
all wavelengths, except for 0.8% DMSO at 590 nm. Therefore, and as broadly stated in the 
literature, the initial cell density may constrain the cytotoxicity outcomes. Anyway, at the light of 
these results, the following MTT assays aiming to test the effect of bacterial extracts on Capan-1 
cellular viability were run at higher initial cell densities coupled with an optimal dose of 1% of 
extract (i.e., 1% DMSO) and absorbance readings at 570 nm, because as it could be observed, at 
higher cell densities (5x104 cells/mL), 1% of DMSO did not affect them. Although the effect of 
DMSO concentration was not herein included in this set of optimization experiments for the initial 
cell density of 7x104 cells/mL, a control with culture medium and 1% (v/v) DMSO was considered 
in the MTT assay performed for the bacterial extracts. 
The cytotoxic effect of the 28 extracts is shown in figure 6. Except for the cell fraction 
extract of M123 strain, all extracts of cell-free and cell fractions induced a significant inhibition 
(p<0.05) of cellular activity. Overall, the percentage of viable/active Capan-1 cells after exposure 
to cell-free fraction extracts ranged between 38 and 76%, whilst to cell fraction extracts 40 to 97% 
of viable cells were calculated, what indicates that the cell-free fraction was generally the most 
cytotoxic. Thereby, this result suggests that the NRPs or hybrids potentially synthesized by these 
marine bacteria cross the cellular membranes and are released to the surrounding environment. 
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Fig.4: Analysis of the average absorbance values measured at different reading times (5 min, 10 min and 15 
min), wavelengths (A - 500 nm, B – 540 nm, C – 570 nm, D – 590 nm) and initial cell densities of Capan-1 
human PDAC cell line, resulting from MTT assay. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.5: Average absorbance values obtained in MTT assay for the testing of DMSO effect considering 
different initial cell densities and measuring wavelengths. Error bars indicate standard deviation and * 
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stands for statistically significant inhibition of cell viability provoked by DMSO relatively to the control, 
within the respective initial cell density (p< 0.05). 
 
Fig.6: Average absorbance values obtained in MTT assay for testing the anticancer activity of bacterial crude 
extracts (cell and cell-free fractions) against Capan-1 PDAC cells. The exposure was run with an initial cell 
density of 7x104 cells/mL and the absorbance readings were performed at 570 nm. Error bars indicate 
standard deviation and * stands for statistically significant inhibition of cell viability provoked by the extract 
relatively to the control (p< 0.05). 
  
  
The more pronounced inhibitions occurred under both fractions of M85, the cell fraction of M68 
and M169, and the cell-free fraction of M125.  
 According to the 16S rDNA-based phylogenetic analysis, they corresponded to species 
belonging to the genera Rhodococcus spp. (M85, M68, M138), Brevibacterium sp. (M169), 
Paracoccus rhizosphaerae (M125), respectively, but also significant inhibitions were detected for 
the extracts of Pseudomonas spp. (M51, M60-M61, M157), Ruegeria spp. (M15, M72), Halomonas 
sp. (M146), Sulfitobacter (M139), and Pseudoalteromonas sp. (M123) species (Fig. 6, Table 3). The 
bioactivities of M60, M61, M85, and M146 are likely to rely on NRPs compounds, given the high 
homology (≥82%) in aminoacid sequences obtained upon comparison with BlastP deposited 
sequences of NRPS biosynthetic gene clusters (Table 4). Though with a lower identity percentage, 
the activity of M51, M123, M139, and M157 strains can also result from NRPS biosynthesis, 
though a more thorough analysis has yet to be undertaken. No studies regarding the Paracoccus 
and Ruegeria genera and its potential of anticancer agents biosynthesis could be found. In 
relation to Rhodococcus genera, the current literature does not show many related reports on 
their cytotoxic effect. However, a study was performed with Rhodococcus strains isolated from a 
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polluted soil, towards the evaluation of the effect of crude extracts obtained from its cell-free 
fraction on human hepatocellular carcinoma cells (HepG2 cell line) and cervical carcinoma cells 
(HeLa cells)235. The authors verified the cytotoxic effect of the Rhodococcus extracts on cell 
viability, hence indicating their antitumor activity against both cell lines. A study with 
Brevibacterium from several coastal areas of South Arabia236, showed the anticancer activity of 
the cell-free fraction of crude extracts against MCF-7 human breast cancer cells, according to the 
outcome of MTT assay, but no effect was recorded against HTC 116 colorectal cancer cells236. 
Considering Halomonas and Sulfitobacter genera (to which belongs M146 and M139, 
respectively), a study was performed to test the bioactivity of strains isolated from deep sea 
brines on MCF-7 cell line, DU145 prostate carcinoma cells and HeLa cells, using the MTT assay237. 
The authors also used the cell-free fraction of the crude extracts and the results turned out to 
show their significant inhibitory action to the three addressed cell lines237. Bacterial 
representatives of the Pseudomonas genus (as M51, M60, M61 and M157) obtained from coastal 
waters were indeed reported to produce anticancer products capable of inhibiting hepatocellular 
carcinoma cells viability, as well as an extract dose-dependent trend could be identified238. In this 
study, the bacteria with anti-hepatocellular-carcinoma abilities presented gene clusters for PKs 
biosynthesis, although the authors believe that other biosynthetic gene clusters might be present 
as well, given the extremely high inhibitory effect observed238. However, those genes could be 
silenced or the primers used for their amplification were not the most adequate238.    
Although, M123 was the only bacterial strain whose cell fraction did not significantly 
affect Capan-1 cells activity, two studies performed with Pseudoalteromonas bacterial strains 
reached opposite results. In the first study, the authors used strains isolated from intertidal zones 
in China Sea239. Among the 29 strains analysed, the cell-free-based crude extracts of two of them 
were active against HeLa cells and BGC-823 stomach cancer cell line239. The specific compound 
responsible for that cytotoxicity was purified and identified as “norharman”, an already known 
compound for its high toxicity239. Also the cell-free crude extracts of other Pseudoalteromonas 
strains collected from marine cold water could inhibit the human A549 lung cancer cell line, based 
on the outcome of MTT assay, being the cytotoxic compound the 4-HBA (4-hydroxybenzoic 
acid)240.   
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Conclusions 
 
Marine cnidarian symbionts can enclose a great biosynthetic potential, which can be of 
major relevance to fight pancreatic cancer. The outcomes herein attained strengthen that a 
molecular screening of NRPs-producing bacteria as a first step to select potential producers of 
bioactive secondary metabolites against PDAC is reliable and pin point a solid study direction. As 
such, from a set of 14 bacterial strains selected through this approach, most derived extracts 
inhibited the cellular activity of a pancreatic cell line. Such activity was partly associated to NRPS 
biosynthetic clusters given the presence of gene sequences of NRPS A domain in those bacteria. 
More tests will be done to better understand the anticancer activity of the extracts of marine 
bacteria, but the promising results reinforce the search for new anticancer drugs in under 
explored marine resources.  
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Final considerations 
 
 
 As final conclusions of this study it is recognized the diversity of possibilities that the 
marine environment offers in terms of biological diversity of macro and, especially, of 
microorganisms. Among these, marine bacteria often living in symbiosis with marine cnidarians, 
enclose a potential to help reaching alternative treatments for several human diseases or health 
problems, given their ability to synthesize bioactive natural compounds.  
 Bacterially-produced secondary metabolites or natural compounds result frequently from 
the expression of NRPS, PKS or NRPS-PKS hybrids gene clusters, which encode the biosynthesis of 
nonribosomal peptides, polyketides and nonribosomal-polyketide hybrids, respectively, with 
varied chemical structures, properties and activities. Getting a deeper knowledge on the genetic 
composition and machinery sustaining the diversity and evolutionary trend of those modular 
enzymes as well as their ubiquity, not only has been widen the discovery of new products but also 
the fundamentals to create novel optimized chemicals through genetic engineering. Such 
approaches will favour the biosynthesis of active compounds to counteract medical limitations 
related with drug resistance against resistant microbial infections or with the low efficacy of 
current cancer therapeutics, among others. Still, more studies directed to the marine 
environment and the biotechnological potential of bacterial symbionts are needed.  
In this context, bacterial symbionts of cnidarian species from the Atlantic Ocean were 
herein explored for screening the biosynthetic potential of NRPs and test the activity of the 
respective bacterial extracts. The results and research accomplished, support the hypothesis that 
a range of bacteria, mainly Proteobacteria and Actinobacteria are responsible for the production 
of diverse NRPs. These clinically relevant products associated with NRPS genes, may represent a 
vigorous and large source of clinical options for the treatment of current threatening and invasive 
diseases, such as pancreatic cancer. Indeed, the corresponding band of NRPS A domain was 
detected in the genomic DNA of 39 strains (22.3% of the tested isolates), among which 14 were 
selected and their crude extracts (cell and/or cell-free fractions) presented activity against a 
human pancreatic cell line (Capan-1), according to the MTT assay outcome. This constituted a 
valuable first step to proceed for isolation and discovery of the anti-cancer NRPs synthesized by 
those marine bacteria for the potential anti-pancreatic cancer control. 
 As such, this study brings novel scientific knowledge regarding NRPs bacterial producers 
isolated from cnidarians, reinforcing the pharmaceutical potential hidden in marine biological and 
ecological niches. In the future, these marine bacteria possessing NRPS genes should be further 
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tested to find out if the produced secondary metabolites exhibit activity against other tumours, 
bacteria, fungi, inflammatory and immunosuppressive diseases, among others. It is hence 
encouraging to look forward and open horizons for the best hope, through the application of 
modern sequencing, chemistry and enzymology tools to uncover bacterial 
metagenomic/metabolomics, to further manipulate and examine their capacity to produce 
relevant NRPS as well as PKS and hybrid enzymes enrolled in the synthesis of novel natural 
products.  
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• Bacterial strains isolated from CF6 did not present PKS or NRPS genes (Table 1, Fig. 2)
• Cnidarians harbouring bacteria with these biosynthetic genes can be ordered as: 
PKS ► CF2 > CF1> CF5> CF3> CF4; 
NRPS ► CF4> CF1> CF5> CF2> CF3;
• Some bacterial strains extracted from CF1, CF2, CF3 and CF5 are PKS-NRPS hybrids because these 
groups exhibit both genes (Fig. 2, Table 1).
• The screening shows a general tendency of a higher representation of NRPS-positive strains than PKS-
positive strains (Table 1). Other authors, however, obtained more PKS representation in marine 
cyanobacteria [11]. 
• The bacteria presenting PKS and NRPS genes will be further studied as to certain the exact compounds
they potentially express, as well as it will be tested their biological activity for different medical applications
(Table 2).
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• Current available drugs to treat several diseases are loosing their efficacy.
• New and alternative compounds/approaches are needed.
• Marine natural products have been isolated and identified from different marine sources like
algae, cnidarians and microorganisms.
• Polyketides (PKs) and non-ribosomal peptides (NRPs) are groups of natural compounds
with a variety of relevant biological activities for medical purposes [10].
• Goal: screening of NRPS and PKS genes in microorganisms isolated from cnidarian
species.
• The results of this screening shows a greater occurrence of NRPS genes in bacteria isolated from cnidarian
species.
• Further studies on the molecular structure, expression/biosynthesis and activity of these genes on these
bacteria will help to unravel potentially new natural compounds.
• Screening for NRPS and PKS genes as indicators of the capacity of bacteria to produce clinically significant
bioactive metabolites constitutes a beneficial and reliable approach.
• Extraction and isolation of bacteria in association with 6 cnidarian species collected in the 
Atlantic ocean (20-38 m depth).  
• Long term storage of pure bacterial isolates.
• Extraction of gDNA from bacterial suspension by heat lysis
• PKS and NRPS genes PCR-screened with degenerate primers (ketosynthase and 
adenylation, respectively). 
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Table 2: Examples of compounds associated with PKS and NRPS genes and PKS-
NRPS hybrids, as well as their biological activities.
Fig. 2: Percentage of bacteria presenting PKS and NRPS genes in each cnidarian species tested. 
Genes Compounds Activities References
PKS Biosurfactants Antimicrobial; Antibiofilm
1
2
Aromatic 
polyketides
Antibiotic; 
Antioxidant; 
Anticancer; 
Immunosuppressive
Anti-inflammatory
3
NRPS Surfactin
Antibiotic; 
Antifungal; 
Antiviral; 
Anti-tumour; 
Hemolytic
4
5
Bacitracin Antibiotic, Antifungal
4
6
Hybrids
Tetramic acids 
(ex.: 
Equisetin, 
Pseurotin A)
Toxicity; 
Neuritogenic 
properties; 
Antifungal;
7
8
9
IV Postgrad 
in 
Biomedicine
Clones PKS NRPS Clones PKS NRPS Clones PKS NRPS Clones PKS NRPS Clones PKS NRPS Clones PKS NRPS Clones PKS NRPS
MT1 ns (-) MT25 (-) (-) MT41 ns (-) MT58 (-) (-) MT69 (-) (+) MT81 (-) (-) MT96 ns (-)
MT2 ns (-) MT26 ns (-) MT42 (-) (+) MT59 (-) (-) MT70 ns (-) MT82 (-) (+) MT97 ns (-)
MT3 ns (-) MT27 ns (-) MT43 ns (-) MT60 (+) (+) MT71 ns (+) MT83 (-) (+) MT98 ns (-)
MT4 ns (-) MT28 ns (-) MT44 (-) (-) MT61 ns (-) MT72 (-) (+) MT84 ns (-) MT99 (-) (-)
MT5 ns (+) MT29 ns (-) MT45 ns (-) MT62 ns (-) MT73 (-) (-) MT85 ns (-) MT100 ns (-)
MT6 ns (+) MT30 ns (-) MT46 (-) (-) MT63 ns (-) MT74 ns (-) MT86 ns (-) MT101 ns (-)
MT7 ns (-) MT31 ns (-) MT47 ns (-) MT64 ns (-) MT75 (-) (-) MT87 ns (-)
MT8 ns (-) MT32 (-) (-) MT48 ns (-) MT65 (-) (-) MT76 ns (-) MT88 ns (-)
MT9 ns (-) MT33 ns (-) MT49 ns (-) MT66 (-) (-) MT77 (-) (-) MT89 (+) (-)
MT10 ns (+) MT34 ns (-) MT50 ns (-) MT67 (-) (-) MT78 (-) (-) MT90 (+) (-)
MT11 (-) (-) MT35 ns (-) MT51 (+) (+) MT68 (-) (-) MT79 (-) (+) MT91 (-) (+)
MT12 ns (-) MT36 ns (-) MT52 ns (-) MT80 ns (-) MT92 (-) (-)
MT13 ns (-) MT37 ns (-) MT53 ns (+) MT93 (-) (+)
MT14 (-) (-) MT38 ns (-) MT54 ns (-) MT94 (-) (-)
MT15 ns (+) MT39 (-) (-) MT55 ns (-) MT95 (-) (-)
MT16 (-) (-) MT40 (+) (+) MT56 ns (-)
MT17 ns (-) MT57 ns (-)
MT18 (-) (-)
MT19 (-) (+)
MT20 ns (-)
MT21 (-) (+)
MT22 (-) (-)
MT23 (+) (+)
MT24 (+) (-)
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